ID

DB00189|APRD00958||

名称

Ethchlorvynol

描述

Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

cas号

113-18-8

唯一标识码

6EIM3851UZ

状态

liquid

组

approved,illicit,withdrawn,

指示

Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents.

药效学

Ethchlorvynol is a sedative drug and schedule IV (USA) controlled substance. It produces cerebral depression, however the exact mechanism of action is not known.

作用机制

Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl^- ionopore at the GABA_A receptor, increasing the duration of time for which the Cl^- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

毒性

Symptoms of overdose include thrombocytopenia.

代谢

About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation.

吸收

Rapidly absorbed from gastrointestinal tract.

半衰期

Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.

分类

description:This compound belongs to the class of organic compounds known as ynones. These are organic compounds containing the ynone functional group, an alpha,beta unsaturated ketone group with the general structure RC#C-C(=O)R' (R' not H).
direct-parent:Ynones
kingdom:Organic compounds
superclass:Organic oxygen compounds
class:Organooxygen compounds
subclass:Carbonyl compounds
alternative-parent:Acetylides
alternative-parent:Chloroalkenes
alternative-parent:Hydrocarbon derivatives
alternative-parent:Organochlorides
alternative-parent:Tertiary alcohols
alternative-parent:Vinyl chlorides
substituent:Acetylide
substituent:Alcohol
substituent:Aliphatic acyclic compound
substituent:Chloroalkene
substituent:Haloalkene
substituent:Hydrocarbon derivative
substituent:Organochloride
substituent:Organohalogen compound
substituent:Tertiary alcohol
substituent:Vinyl chloride
substituent:Vinyl halide
substituent:Ynone

消除途径

种类

Alcohols
D000438
Central Nervous System Agents
D002491
Central Nervous System Depressants
D002492
Chlorohydrins
D002728
Hypnotics and Sedatives
D006993
Nervous System
D009420
Psycholeptics

盐类

蛋白质结合

35-50%

清除

同义词

language:english; code:; name;1-chloro-3-ethyl-1-penten-4-yn-3-ol
language:english; code:; name;1-Chloro-3-ethyl-pent-1-en-4-yn-3-ol
language:english; code:; name;3-(beta-chlorovinyl)-1-pentyn-3-ol
language:english; code:; name;3-(β-chlorovinyl)-1-pentyn-3-ol
language:spanish; code:inn; name;etclorvinol
language:english; code:inn/ban/usan; name;Ethchlorvynol
language:english; code:; name;ethyl β-chlorovinyl ethynyl carbinol
language:english; code:; name;β-chlorovinyl ethyl ethynyl carbinol

国际品牌

ArvynolPfizerNostelDainipponPlacidylAbbottRoeridormPfizer-RoerigSerenesilAbbott

配送量

产品

name:Placidyl Cap 200mg
labeller:Abbott
ndc-id:
ndc-product-code:
dpd-id:00000019
ema-product-code:
ema-ma-number:
started-marketing-on:1956-12-31
ended-marketing-on:2008-06-10
dosage-form:Capsule
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Placidyl Cap 500mg
labeller:Abbott
ndc-id:
ndc-product-code:
dpd-id:00000027
ema-product-code:
ema-ma-number:
started-marketing-on:1952-12-31
ended-marketing-on:2008-06-06
dosage-form:Capsule
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Placidyl Cap 750mg
labeller:Abbott
ndc-id:
ndc-product-code:
dpd-id:00228893
ema-product-code:
ema-ma-number:
started-marketing-on:1971-12-31
ended-marketing-on:2008-06-06
dosage-form:Capsule
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD

混合物

name:Placidyl Cap 750mg
ingredients:Ethchlorvynol
name:Placidyl Cap 200mg
ingredients:Ethchlorvynol
name:Placidyl Cap 500mg
ingredients:Ethchlorvynol

包装者

生产者

generic:是; url:; name;Banner pharmacaps inc
generic:否; url:; name;Abbott laboratories pharmaceutical products div

价格

受影响的生物体

Humans and other mammals

剂量

form:Capsule
route:Oral
strength:

atc代码

Other hypnotics and sedatives
HYPNOTICS AND SEDATIVES
PSYCHOLEPTICS
NERVOUS SYSTEM

fda标签

化学品安全技术说明书

专利

食物相互作用

Avoid alcohol.Take with food. Food reduces irritation.

药物相互作用

DB00921
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
DB00470
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
DB00450
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
DB00956
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DB00557
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
DB00653
The therapeutic efficacy of Ethchlorvynol can be increased when used in combination with Magnesium sulfate.
DB01403
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
DB00765
Ethchlorvynol may increase the sedative activities of Metyrosine.
DB01017
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
DB00370
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DB00486
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
DB01173
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DB09117
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
DB08883
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
DB00413
Ethchlorvynol may increase the sedative activities of Pramipexole.
DB00268
Ethchlorvynol may increase the sedative activities of Ropinirole.
DB05271
Ethchlorvynol may increase the sedative activities of Rotigotine.
DB06201
The risk or severity of adverse effects can be increased when Rufinamide is combined with Ethchlorvynol.
DB09034
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
DB06204
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
DB01041
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DB00425
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DB00333
The risk or severity of adverse effects can be increased when Methadone is combined with Ethchlorvynol.
DB09072
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
DB00898
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
DB00972
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DB00484
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
DB00176
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluvoxamine.
DB00215
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Citalopram.
DB00476
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Duloxetine.
DB00656
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trazodone.
DB00715
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paroxetine.
DB01104
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertraline.
DB01105
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sibutramine.
DB01149
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nefazodone.
DB01175
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Escitalopram.
DB04832
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zimelidine.
DB04884
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapoxetine.
DB04896
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Milnacipran.
DB06700
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desvenlafaxine.
DB06731
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Seproxetine.
DB08918
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomilnacipran.
DB08953
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Indalpine.
DB12693
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ritanserin.
DB13233
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alaproclate.
DB00209
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Trospium.
DB00219
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.
DB00245
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
DB00280
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
DB00332
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.
DB00340
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Metixene.
DB00342
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.
DB00354
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Buclizine.
DB00376
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
DB00383
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.
DB00387
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.
DB00392
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Profenamine.
DB00424
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
DB00434
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
DB00458
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
DB00462
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine bromide.
DB00496
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
DB00505
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.
DB00517
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Anisotropine methylbromide.
DB00540
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
DB00543
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
DB00572
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Atropine.
DB00622
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.
DB00670
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.
DB00725
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.
DB00767
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Benzquinamide.
DB00777
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.
DB00782
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
DB00804
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
DB00810
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Biperiden.
DB00907
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
DB00908
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Quinidine.
DB00934
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
DB00940
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Methantheline.
DB00942
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Cycrimine.
DB00986
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
DB01036
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
DB01062
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
DB01142
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DB01148
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
DB01151
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
DB01231
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Diphenidol.
DB01409
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Tiotropium.
DB01591
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
DB01625
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.
DB04843
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.
DB06153
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.
DB06702
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
DB06787
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.
DB08801
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.
DB08897
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
DB08997
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.
DB09076
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Umeclidinium.
DB09089
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.
DB09167
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.
DB09262
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Imidafenacin.
DB09300
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.
DB11235
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.
DB11315
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
DB11855
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.
DB12086
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Oxitropium.
DB12278
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Propiverine.
DB12526
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Batefenterol.
DB12554
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
DB13252
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.
DB13254
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Prifinium.
DB13351
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.
DB13369
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Benzilone.
DB13380
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Difemerine.
DB13413
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Phenglutarimide.
DB13448
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Mazaticol.
DB13468
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.
DB13500
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Otilonium.
DB13507
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Poldine.
DB13542
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Bevonium.
DB13581
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Rociverine.
DB13619
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.
DB13636
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Etanautine.
DB13666
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Tiemonium iodide.
DB13678
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.
DB13695
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Penthienate.
DB13720
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.
DB13738
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Camylofin.
DB13759
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Fenpiverinium.
DB13769
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Emetonium iodide.
DB13844
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.
DB13850
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Timepidium.
DB09007
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.
DB01198
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zopiclone.
DB00042
The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ethchlorvynol.
DB00083
The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethchlorvynol.
DB00150
The risk or severity of adverse effects can be increased when Tryptophan is combined with Ethchlorvynol.
DB00181
The risk or severity of adverse effects can be increased when Baclofen is combined with Ethchlorvynol.
DB00182
The risk or severity of adverse effects can be increased when Amphetamine is combined with Ethchlorvynol.
DB00186
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ethchlorvynol.
DB00202
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Succinylcholine.
DB00206
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Reserpine.
DB00216
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eletriptan.
DB00228
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Enflurane.
DB00231
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Temazepam.
DB00234
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Reboxetine.
DB00237
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butabarbital.
DB00241
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butalbital.
DB00247
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methysergide.
DB00248
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cabergoline.
DB00252
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenytoin.
DB00273
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Topiramate.
DB00283
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clemastine.
DB00285
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Venlafaxine.
DB00289
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Atomoxetine.
DB00292
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etomidate.
DB00295
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Morphine.
DB00306
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Talbutal.
DB00312
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pentobarbital.
DB00313
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Valproic acid.
DB00315
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zolmitriptan.
DB00318
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Codeine.
DB00320
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydroergotamine.
DB00323
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tolcapone.
DB00327
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hydromorphone.
DB00334
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Olanzapine.
DB00341
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cetirizine.
DB00344
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Protriptyline.
DB00347
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trimethadione.
DB00349
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clobazam.
DB00356
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorzoxazone.
DB00363
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clozapine.
DB00371
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meprobamate.
DB00372
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiethylperazine.
DB00377
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Palonosetron.
DB00391
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sulpiride.
DB00404
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alprazolam.
DB00405
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexbrompheniramine.
DB00408
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loxapine.
DB00409
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remoxipride.
DB00416
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metocurine iodide.
DB00418
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Secobarbital.
DB00420
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promazine.
DB00423
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methocarbamol.
DB00427
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triprolidine.
DB00433
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prochlorperazine.
DB00454
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meperidine.
DB00463
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metharbital.
DB00468
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quinine.
DB00474
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methohexital.
DB00475
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlordiazepoxide.
DB00477
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorpromazine.
DB00483
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gallamine triethiodide.
DB00494
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Entacapone.
DB00497
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxycodone.
DB00508
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triflupromazine.
DB00514
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextromethorphan.
DB00532
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mephenytoin.
DB00546
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Adinazolam.
DB00555
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lamotrigine.
DB00564
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbamazepine.
DB00565
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cisatracurium.
DB00574
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fenfluramine.
DB00579
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mazindol.
DB00588
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluticasone propionate.
DB00589
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lisuride.
DB00593
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethosuximide.
DB00599
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiopental.
DB00601
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Linezolid.
DB00604
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cisapride.
DB00611
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butorphanol.
DB00614
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Furazolidone.
DB00617
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paramethadione.
DB00623
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluphenazine.
DB00625
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Efavirenz.
DB00628
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clorazepic acid.
DB00633
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexmedetomidine.
DB00645
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dyclonine.
DB00647
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextropropoxyphene.
DB00652
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pentazocine.
DB00660
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metaxalone.
DB00662
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trimethobenzamide.
DB00669
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sumatriptan.
DB00679
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thioridazine.
DB00680
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Moricizine.
DB00683
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Midazolam.
DB00690
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flurazepam.
DB00696
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ergotamine.
DB00697
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tizanidine.
DB00708
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sufentanil.
DB00714
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Apomorphine.
DB00721
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Procaine.
DB00726
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trimipramine.
DB00728
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Rocuronium.
DB00732
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Atracurium besylate.
DB00734
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Risperidone.
DB00737
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meclizine.
DB00740
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Riluzole.
DB00747
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Scopolamine.
DB00748
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbinoxamine.
DB00752
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tranylcypromine.
DB00753
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Isoflurane.
DB00754
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethotoin.
DB00757
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dolasetron.
DB00771
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clidinium.
DB00776
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxcarbazepine.
DB00780
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenelzine.
DB00794
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Primidone.
DB00801
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halazepam.
DB00802
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alfentanil.
DB00805
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Minaprine.
DB00813
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fentanyl.
DB00818
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propofol.
DB00819
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acetazolamide.
DB00829
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diazepam.
DB00831
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trifluoperazine.
DB00832
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phensuximide.
DB00835
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brompheniramine.
DB00837
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Progabide.
DB00842
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxazepam.
DB00843
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Donepezil.
DB00844
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nalbuphine.
DB00849
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methylphenobarbital.
DB00850
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perphenazine.
DB00854
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levorphanol.
DB00865
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzphetamine.
DB00866
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alprenolol.
DB00875
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flupentixol.
DB00889
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Granisetron.
DB00897
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triazolam.
DB00899
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remifentanil.
DB00904
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ondansetron.
DB00906
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiagabine.
DB00909
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zonisamide.
DB00918
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Almotriptan.
DB00933
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mesoridazine.
DB00937
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diethylpropion.
DB00941
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hexafluronium.
DB00949
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Felbamate.
DB00952
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Naratriptan.
DB00953
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Rizatriptan.
DB00960
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pindolol.
DB00962
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zaleplon.
DB00967
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desloratadine.
DB00969
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alosetron.
DB00980
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ramelteon.
DB00985
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dimenhydrinate.
DB00996
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gabapentin.
DB00998
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Frovatriptan.
DB01018
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Guanfacine.
DB01028
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methoxyflurane.
DB01037
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Selegiline.
DB01049
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ergoloid mesylate.
DB01063
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acetophenazine.
DB01065
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Melatonin.
DB01068
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonazepam.
DB01069
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promethazine.
DB01075
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diphenhydramine.
DB01080
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vigabatrin.
DB01081
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diphenoxylate.
DB01100
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pimozide.
DB01107
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methyprylon.
DB01114
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorpheniramine.
DB01121
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenacemide.
DB01135
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doxacurium.
DB01154
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiamylal.
DB01156
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bupropion.
DB01159
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halothane.
DB01168
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Procarbazine.
DB01171
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Moclobemide.
DB01174
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenobarbital.
DB01176
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclizine.
DB01178
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlormezanone.
DB01186
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pergolide.
DB01189
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desflurane.
DB01192
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxymorphone.
DB01199
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tubocurarine.
DB01200
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromocriptine.
DB01202
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levetiracetam.
DB01209
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dezocine.
DB01215
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Estazolam.
DB01219
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dantrolene.
DB01221
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketamine.
DB01224
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quetiapine.
DB01226
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mivacurium.
DB01227
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levacetylmethadol.
DB01235
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levodopa.
DB01236
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sevoflurane.
DB01238
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aripiprazole.
DB01239
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorprothixene.
DB01242
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clomipramine.
DB01245
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Decamethonium.
DB01246
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alimemazine.
DB01247
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Isocarboxazid.
DB01253
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ergometrine.
DB01267
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paliperidone.
DB01320
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fosphenytoin.
DB01323
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with St. John's Wort.
DB01336
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metocurine.
DB01337
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pancuronium.
DB01338
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipecuronium.
DB01339
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vecuronium.
DB01351
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amobarbital.
DB01352
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aprobarbital.
DB01353
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butobarbital.
DB01354
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Heptabarbital.
DB01355
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hexobarbital.
DB01356
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lithium cation.
DB01359
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Penbutolol.
DB01367
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Rasagiline.
DB01392
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Yohimbine.
DB01433
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methadyl acetate.
DB01437
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Glutethimide.
DB01440
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with gamma-Hydroxybutyric acid.
DB01442
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with MMDA.
DB01445
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bufotenine.
DB01450
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydroetorphine.
DB01452
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diamorphine.
DB01454
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Midomafetamine.
DB01463
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fencamfamin.
DB01466
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethylmorphine.
DB01472
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with 4-Methoxyamphetamine.
DB01483
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Barbital.
DB01484
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with 4-Bromo-2,5-dimethoxyamphetamine.
DB01488
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dimethyltryptamine.
DB01489
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Camazepam.
DB01495
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dichloralphenazone.
DB01497
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etorphine.
DB01501
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Difenoxin.
DB01509
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tenamfetamine.
DB01511
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Delorazepam.
DB01529
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextromoramide.
DB01531
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desomorphine.
DB01534
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorhexadol.
DB01535
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carfentanil.
DB01544
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flunitrazepam.
DB01545
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl loflazepate.
DB01547
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Drotebanol.
DB01551
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydrocodeine.
DB01553
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cloxazolam.
DB01555
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alphacetylmethadol.
DB01558
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromazepam.
DB01559
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clotiazepam.
DB01560
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cathinone.
DB01563
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloral hydrate.
DB01565
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydromorphine.
DB01567
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fludiazepam.
DB01577
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metamfetamine.
DB01580
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxprenolol.
DB01587
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketazolam.
DB01588
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prazepam.
DB01589
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quazepam.
DB01594
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cinolazepam.
DB01595
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nitrazepam.
DB01608
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Periciazine.
DB01614
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acepromazine.
DB01615
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aceprometazine.
DB01616
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alverine.
DB01618
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Molindone.
DB01621
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipotiazine.
DB01622
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thioproperazine.
DB01623
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiothixene.
DB01624
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zuclopenthixol.
DB01626
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pargyline.
DB01954
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Rolipram.
DB02207
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with 7-Nitroindazole.
DB02234
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with S-Ethylisothiourea.
DB02852
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Domoic Acid.
DB02959
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxitriptan.
DB03575
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phencyclidine.
DB04017
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clorgiline.
DB04165
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Valpromide.
DB04325
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenethylamine.
DB04599
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aniracetam.
DB04818
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Iproniazid.
DB04819
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methapyrilene.
DB04820
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nialamide.
DB04821
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nomifensine.
DB04827
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Urethane.
DB04829
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lysergic acid diethylamide.
DB04833
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methaqualone.
DB04834
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Rapacuronium.
DB04836
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amineptine.
DB04841
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flunarizine.
DB04842
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluspirilene.
DB04871
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lorcaserin.
DB04872
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Osanetant.
DB04885
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cilansetron.
DB04888
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bifeprunox.
DB04903
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pagoclone.
DB04908
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flibanserin.
DB04917
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Renzapride.
DB04946
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Iloperidone.
DB04953
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ezogabine.
DB05227
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with APD791.
DB05232
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrodotoxin.
DB05246
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methsuximide.
DB05316
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pimavanserin.
DB05541
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brivaracetam.
DB05542
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Naronapride.
DB05562
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Naluzotan.
DB05607
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with PRX-08066.
DB05687
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with BL-1020.
DB05710
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gantacurium.
DB06016
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cariprazine.
DB06077
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lumateperone.
DB06109
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with YKP-1358.
DB06144
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertindole.
DB06148
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mianserin.
DB06216
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Asenapine.
DB06218
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lacosamide.
DB06264
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tolperisone.
DB06282
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levocetirizine.
DB06288
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amisulpride.
DB06446
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dotarizine.
DB06458
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remacemide.
DB06470
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clomethiazole.
DB06512
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Deramciclane.
DB06527
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tramiprosate.
DB06529
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ocinaplon.
DB06554
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gaboxadol.
DB06579
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Adipiplon.
DB06582
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextofisopam.
DB06594
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Agomelatine.
DB06654
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Safinamide.
DB06660
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Saredutant.
DB06678
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Esmirtazapine.
DB06684
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vilazodone.
DB06690
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nitrous oxide.
DB06691
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mepyramine.
DB06701
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexmethylphenidate.
DB06716
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fospropofol.
DB06738
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketobemidone.
DB06753
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triclofos.
DB06770
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzyl alcohol.
DB06797
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mebutamate.
DB08059
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Wortmannin.
DB08329
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sulthiame.
DB08550
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
DB08810
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cinitapride.
DB08811
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tofisopam.
DB08815
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lurasidone.
DB08839
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Serotonin.
DB08861
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with DPDPE.
DB08872
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gabapentin enacarbil.
DB08892
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Arbaclofen Placarbil.
DB08910
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pomalidomide.
DB08922
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perospirone.
DB08927
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amperozide.
DB08954
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ifenprodil.
DB08960
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hexamethonium.
DB08986
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etifoxine.
DB08992
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eperisone.
DB08996
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dimetacrine.
DB09000
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyamemazine.
DB09001
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Barbexaclone.
DB09011
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Beclamide.
DB09014
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Captodiame.
DB09016
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butriptyline.
DB09017
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brotizolam.
DB09021
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzoctamine.
DB09023
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benactyzine.
DB09068
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vortioxetine.
DB09071
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tasimelteon.
DB09118
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Stiripentol.
DB09119
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eslicarbazepine acetate.
DB09128
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brexpiprazole.
DB09166
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etizolam.
DB09174
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lofentanil.
DB09184
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Edivoxetine.
DB09185
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Viloxazine.
DB09186
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nisoxetine.
DB09187
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lortalamine.
DB09190
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Talopram.
DB09194
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etoperidone.
DB09223
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Blonanserin.
DB09224
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Melperone.
DB09225
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zotepine.
DB09226
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brilaroxazine.
DB09241
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methylene blue.
DB09243
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hydracarbazine.
DB09244
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pirlindole.
DB09245
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Toloxatone.
DB09246
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benmoxin.
DB09247
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Iproclozide.
DB09248
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mebanazine.
DB09249
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Octamoxin.
DB09250
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pheniprazine.
DB09251
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenoxypropazine.
DB09252
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pivhydrazine.
DB09253
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Safrazine.
DB09254
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Caroxazone.
DB09286
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipamperone.
DB09289
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tianeptine.
DB09290
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ramosetron.
DB09307
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxaprotiline.
DB11130
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Opium.
DB11156
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pyrantel.
DB11371
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alfaxalone.
DB11376
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Azaperone.
DB11400
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doramectin.
DB11428
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Medetomidine.
DB11477
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Xylazine.
DB11540
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propiopromazine.
DB11543
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Romifidine.
DB11549
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiletamine.
DB11552
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tricaine.
DB11555
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zolazepam.
DB11556
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Detomidine.
DB11582
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiocolchicoside.
DB11609
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Normethadone.
DB11664
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Psilocybin.
DB11675
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mosapride.
DB11686
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Iferanserin.
DB11699
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tropisetron.
DB11755
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrahydrocannabivarin.
DB11859
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brexanolone.
DB11868
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etiracetam.
DB11889
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lanicemine.
DB11957
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Idalopirdine.
DB12071
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vabicaserin.
DB12093
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrahydropalmatine.
DB12105
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Imagabalin.
DB12110
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with m-Chlorophenylpiperazine.
DB12111
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with MK-212.
DB12131
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vinpocetine.
DB12163
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sarpogrelate.
DB12177
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eplivanserin.
DB12184
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gepirone.
DB12229
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cerlapirdine.
DB12273
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ecopipam.
DB12308
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eltanolone.
DB12327
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Salvinorin A.
DB12338
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carisbamate.
DB12361
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Piclozotan.
DB12395
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Esreboxetine.
DB12401
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromperidol.
DB12427
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Orvepitant.
DB12465
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketanserin.
DB12492
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Piritramide.
DB12518
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Raclopride.
DB12537
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzodiazepine.
DB12576
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with AZD-3043.
DB12590
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Indiplon.
DB12661
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Urapidil.
DB12710
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perazine.
DB12725
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with TD-8954.
DB12833
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tandospirone.
DB12867
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benperidol.
DB12883
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eltoprazine.
DB12930
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Opipramol.
DB12951
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pivagabine.
DB12958
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prothipendyl.
DB12989
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Neosaxitoxin.
DB13014
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hypericin.
DB13025
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiapride.
DB13082
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nefiracetam.
DB13099
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Valnoctamide.
DB13114
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amitriptylinoxide.
DB13160
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alphaprodine.
DB13213
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butaperazine.
DB13219
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Medifoxamine.
DB13221
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Apronalide.
DB13225
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dibenzepin.
DB13234
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propanidid.
DB13246
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quinupramine.
DB13253
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Proxibarbal.
DB13256
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clothiapine.
DB13273
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sultopride.
DB13295
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Atracurium.
DB13303
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Febarbamate.
DB13323
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trichloroethylene.
DB13324
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrazepam.
DB13331
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pyrithyldione.
DB13335
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pinazepam.
DB13352
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Deanol.
DB13354
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenprobamate.
DB13357
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Styramate.
DB13362
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pheneturide.
DB13370
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromisoval.
DB13377
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vinbarbital.
DB13382
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorproethazine.
DB13384
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Melitracen.
DB13396
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Neocitrullamon.
DB13402
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acetylglycinamide chloral hydrate.
DB13403
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxypertine.
DB13411
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lofepramine.
DB13414
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fenyramidol.
DB13420
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiazinam.
DB13437
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Medazepam.
DB13454
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nicomorphine.
DB13455
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenibut.
DB13457
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxaflozane.
DB13478
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meptazinol.
DB13496
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Iprindole.
DB13505
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Emepronium.
DB13520
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metergoline.
DB13522
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mebicar.
DB13523
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Veralipride.
DB13534
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gedocarnil.
DB13541
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Iprazochrome.
DB13550
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bifemelane.
DB13552
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trifluperidol.
DB13554
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Moperone.
DB13557
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiopropazate.
DB13572
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Emylcamate.
DB13577
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Allobarbital.
DB13584
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gallamine.
DB13588
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Naftidrofuryl.
DB13598
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diethyl ether.
DB13601
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxiracetam.
DB13605
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenoperidine.
DB13606
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenazocine.
DB13623
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fabomotizole.
DB13642
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pridinol.
DB13643
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loprazolam.
DB13648
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alcuronium.
DB13662
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hexapropymate.
DB13665
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluanisone.
DB13676
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mosapramine.
DB13687
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Niaprazine.
DB13690
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vinyl ether.
DB13733
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methylpentynol.
DB13737
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclobarbital.
DB13745
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fazadinium bromide.
DB13754
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mephenoxalone.
DB13770
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vinylbital.
DB13782
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Imipramine oxide.
DB13784
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dixyrazine.
DB13787
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tilidine.
DB13791
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Penfluridol.
DB13799
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethadione.
DB13805
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Reposal.
DB13817
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbromal.
DB13837
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doxefazepam.
DB13841
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clopenthixol.
DB13872
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lormetazepam.
DB13875
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Harmaline.
DB13876
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brofaromine.
DB13940
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
DB13948
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.
DB13984
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclopropane.
DB13993
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with MRK-409.
DB14010
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with 5-methoxy-N,N-dimethyltryptamine.
DB14028
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nordazepam.
DB14050
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cannabidivarin.
DB14185
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aripiprazole lauroxil.
DB14509
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lithium carbonate.
DB14575
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eslicarbazepine.
DB14651
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perphenazine enanthate.
DB14672
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxazepam acetate.
DB14715
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cinazepam.
DB14718
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pyrazolam.
DB14719
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bentazepam.
DB14754
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Solriamfetol.
DB15203
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with JNJ-26489112.
DB15360
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carfentanil, C-11.
DB11951
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lemborexant.
DB12404
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remimazolam.
DB00751
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Epinastine.
DB00230
The therapeutic efficacy of Ethchlorvynol can be increased when used in combination with Pregabalin.
DB04844
The risk or severity of sedation and somnolence can be increased when Ethchlorvynol is combined with Tetrabenazine.
DB12161
The risk or severity of sedation and somnolence can be increased when Ethchlorvynol is combined with Deutetrabenazine.
DB04948
The therapeutic efficacy of Ethchlorvynol can be increased when used in combination with Lofexidine.
DB05077
The risk or severity of adverse effects can be increased when SLV319 is combined with Ethchlorvynol.
DB06155
The risk or severity of adverse effects can be increased when Rimonabant is combined with Ethchlorvynol.
DB06624
The risk or severity of adverse effects can be increased when Taranabant is combined with Ethchlorvynol.
DB09061
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Ethchlorvynol.
DB11903
The risk or severity of adverse effects can be increased when GW842166 is combined with Ethchlorvynol.
DB12193
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Ethchlorvynol.
DB12649
The risk or severity of adverse effects can be increased when Ibipinabant is combined with Ethchlorvynol.
DB13070
The risk or severity of adverse effects can be increased when Surinabant is combined with Ethchlorvynol.
DB13950
The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Ethchlorvynol.
DB14011
The risk or severity of adverse effects can be increased when Nabiximols is combined with Ethchlorvynol.
DB14043
The risk or severity of adverse effects can be increased when Palmidrol is combined with Ethchlorvynol.
DB14737
The risk or severity of adverse effects can be increased when Cannabinol is combined with Ethchlorvynol.
DB00321
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethchlorvynol.
DB11823
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Esketamine.
DB00395
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethchlorvynol.
DB06711
The risk or severity of CNS depression can be increased when Naphazoline is combined with Ethchlorvynol.
DB00402
The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Eszopiclone.
DB00575
The risk or severity of sedation can be increased when Clonidine is combined with Ethchlorvynol.
DB00924
The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Cyclobenzaprine.
DB01233
The risk or severity of sedation can be increased when Metoclopramide is combined with Ethchlorvynol.
DB11732
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lasmiditan.
DB00193
The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Tramadol.
DB00246
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ziprasidone.
DB00502
The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Haloperidol.
DB06283
The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Ziconotide.
DB00472
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.
DB14881
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Ethchlorvynol is combined with Oliceridine.

序列

实验性质

Boiling Point
28.5-30
Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas. Pfizer & Co., Inc.
logP
1.8

外部标识符

resource：Drugs Product Database (DPD)
identifier：6015
resource：ChEBI
identifier：4882
resource：PubChem Compound
identifier：5281077
resource：PubChem Substance
identifier：46505006
resource：KEGG Compound
identifier：C07833
resource：KEGG Drug
identifier：D00704
resource：ChemSpider
identifier：4444534
resource：PharmGKB
identifier：PA164746383
resource：Therapeutic Targets Database
identifier：DAP000163
resource：Wikipedia
identifier：Ethchlorvynol
resource：ChEMBL
identifier：CHEMBL591
resource：RxCUI
identifier：4118

外部链接

Drugs.com
http://www.drugs.com/cons/ethchlorvynol.html

路径

目标

id:BE0004797
name:GABA(A) Receptor
organism:Humans
action:positive allosteric modulator
Smeyatsky N, Baldwin D, Botros W, Gura R, Kurian T, Lambert MT, Patel AG, Steinert J, Priest RG: The treatment of sleep disorders. S Afr Med J. 1992 May 2;Suppl:1-8.
known-action:yes
name:Gamma-aminobutyric acid receptor subunit alpha-1
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
gene-name:GABRA1
locus:5q34-q35
cellular-location:Cell junction
transmembrane-regions:252-273 279-300 313-334 422-443
signal-regions:1-27
theoretical-pi:9.61
molecular-weight:51801.395
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4075GenAtlasGABRA1GenBank Gene DatabaseX13584GenBank Protein Database31631IUPHAR404Guide to Pharmacology404UniProtKBP14867UniProt AccessionGBRA1_HUMAN
synonyms:GABA(A) receptor subunit alpha-1
amino-acid-sequence:>lcl|BSEQ0010561|Gamma-aminobutyric acid receptor subunit alpha-1 MRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLLDGYDNRLRPG LGERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMASK IWTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHAC PLKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVM TTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGKSVVPEKPKKVKDP LIKKNNTYAPTATSYTPNLARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKID RLSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ
gene-sequence:>lcl|BSEQ0010562|Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1) ATGAGGAAAAGTCCAGGTCTGTCTGACTGTCTTTGGGCCTGGATCCTCCTTCTGAGCACA CTGACTGGAAGAAGCTATGGACAGCCGTCATTACAAGATGAACTTAAAGACAATACCACT GTCTTCACCAGGATTTTGGACAGACTCCTAGATGGTTATGACAATCGCCTGAGACCAGGA TTGGGAGAGCGTGTAACCGAAGTGAAGACTGATATCTTCGTCACCAGTTTCGGACCCGTT TCAGACCATGATATGGAATATACAATAGATGTATTTTTCCGTCAAAGCTGGAAGGATGAA AGGTTAAAATTTAAAGGACCTATGACAGTCCTCCGGTTAAATAACCTAATGGCAAGTAAA ATCTGGACTCCGGACACATTTTTCCACAATGGAAAGAAGTCAGTGGCCCACAACATGACC ATGCCCAACAAACTCCTGCGGATCACAGAGGATGGCACCTTGCTGTACACCATGAGGCTG ACAGTGAGAGCTGAATGTCCGATGCATTTGGAGGACTTCCCTATGGATGCCCATGCTTGC CCACTAAAATTTGGAAGTTATGCTTATACAAGAGCAGAAGTTGTTTATGAATGGACCAGA GAGCCAGCACGCTCAGTGGTTGTAGCAGAAGATGGATCACGTCTAAACCAGTATGACCTT CTTGGACAAACAGTAGACTCTGGAATTGTCCAGTCAAGTACAGGAGAATATGTTGTTATG ACCACTCATTTCCACTTGAAGAGAAAGATTGGCTACTTTGTTATTCAAACATACCTGCCA TGCATAATGACAGTGATTCTCTCACAAGTCTCCTTCTGGCTCAACAGAGAGTCTGTACCA GCAAGAACTGTCTTTGGAGTAACAACTGTGCTCACCATGACAACATTGAGCATCAGTGCC AGAAACTCCCTCCCTAAGGTGGCTTATGCAACAGCTATGGATTGGTTTATTGCCGTGTGC TATGCCTTTGTGTTCTCAGCTCTGATTGAGTTTGCCACAGTAAACTATTTCACTAAGAGA GGTTATGCATGGGATGGCAAAAGTGTGGTTCCAGAAAAGCCAAAGAAAGTAAAGGATCCT CTTATTAAGAAAAACAACACTTACGCTCCAACAGCAACCAGCTACACCCCTAATTTGGCC AGGGGCGACCCGGGCTTAGCCACCATTGCTAAAAGTGCAACCATAGAACCTAAAGAGGTC AAGCCCGAAACAAAACCACCAGAACCCAAGAAAACCTTTAACAGTGTCAGCAAAATTGAC CGACTGTCAAGAATAGCCTTCCCGCTGCTATTTGGAATCTTTAACTTAGTCTACTGGGCT ACGTATTTAAACAGAGAGCCTCAGCTAAAAGCCCCCACACCACATCAATAG
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA receptor complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctiondrug bindingfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesscellular response to histamineprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesssynaptic transmission, GABAergicprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit alpha-2
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA2
locus:4p12
cellular-location:Cell junction
transmembrane-regions:252-273 279-300 313-334 420-441
signal-regions:1-28
theoretical-pi:9.41
molecular-weight:51325.85
chromosome-location:4
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4076GenAtlasGABRA2GenBank Gene DatabaseS62907GenBank Protein Database386422IUPHAR405Guide to Pharmacology405UniProtKBP47869UniProt AccessionGBRA2_HUMAN
synonyms:GABA(A) receptor subunit alpha-2
amino-acid-sequence:>lcl|BSEQ0037005|Gamma-aminobutyric acid receptor subunit alpha-2 MKTKLNIYNMQFLLFVFLVWDPARLVLANIQEDEAKNNITIFTRILDRLLDGYDNRLRPG LGDSITEVFTNIYVTSFGPVSDTDMEYTIDVFFRQKWKDERLKFKGPMNILRLNNLMASK IWTPDTFFHNGKKSVAHNMTMPNKLLRIQDDGTLLYTMRLTVQAECPMHLEDFPMDAHSC PLKFGSYAYTTSEVTYIWTYNASDSVQVAPDGSRLNQYDLLGQSIGKETIKSSTGEYTVM TAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKSVVNDKKKEKASV MIQNNAYAVAVANYAPNLSKDPVLSTISKSATTPEPNKKPENKPAEAKKTFNSVSKIDRM SRIVFPVLFGTFNLVYWATYLNREPVLGVSP
gene-sequence:>lcl|BSEQ0010268|Gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2) ATGAAGACAAAATTGAACATCTACAACATGCAGTTCCTGCTTTTTGTTTTCTTGGTGTGG GACCCTGCCAGGTTGGTGCTGGCTAACATCCAAGAAGATGAGGCTAAAAATAACATTACC ATCTTTACGAGAATTCTTGACAGACTTCTGGATGGTTACGATAATCGGCTTAGACCAGGA CTGGGAGACAGTATTACTGAAGTCTTCACTAACATCTACGTGACCAGTTTTGGCCCTGTC TCAGATACAGATATGGAATATACAATTGATGTTTTCTTTCGACAAAAATGGAAAGATGAA CGTTTAAAATTTAAAGGTCCTATGAATATCCTTCGACTAAACAATTTAATGGCTAGCAAA ATCTGGACTCCAGATACCTTTTTTCACAATGGGAAAAAATCAGTAGCTCATAATATGACA ATGCCAAATAAGTTGCTTCGAATTCAGGATGATGGGACTCTGCTGTATACCATGAGGCTT ACAGTTCAAGCTGAATGCCCAATGCACTTGGAGGATTTCCCAATGGATGCTCATTCATGT CCTCTGAAATTTGGCAGCTATGCATATACAACTTCAGAGGTCACTTATATTTGGACTTAC AATGCATCTGATTCAGTACAGGTTGCTCCTGATGGCTCTAGGTTAAATCAATATGACCTG CTGGGCCAATCAATCGGAAAGGAGACAATTAAATCCAGTACAGGTGAATATACTGTAATG ACAGCTCATTTCCACCTGAAAAGAAAAATTGGGTATTTTGTGATTCAAACCTATCTGCCT TGCATCATGACTGTCATTCTCTCCCAAGTTTCATTCTGGCTTAACAGAGAATCTGTGCCT GCAAGAACTGTGTTTGGAGTAACAACTGTCCTAACAATGACAACTCTAAGCATCAGTGCT CGGAATTCTCTCCCCAAAGTGGCTTATGCAACTGCCATGGACTGGTTTATTGCTGTTTGT TATGCATTTGTGTTCTCTGCCCTAATTGAATTTGCAACTGTTAATTACTTCACCAAAAGA GGATGGGCTTGGGATGGGAAGAGTGTAGTAAATGACAAGAAAAAAGAAAAGGCTTCCGTT ATGATACAGAACAACGCTTATGCAGTGGCTGTTGCCAATTATGCCCCGAATCTTTCAAAA GATCCAGTTCTCTCCACCATCTCCAAGAGTGCAACCACGCCAGAACCCAACAAGAAGCCA GAAAACAAGCCAGCTGAAGCAAAGAAAACTTTCAACAGTGTTAGCAAAATTGACAGAATG TCCAGAATAGTTTTTCCAGTTTTGTTTGGTACCTTTAATTTAGTTTACTGGGCTACATAT TTAAACAGAGAACCTGTATTAGGGGTCAGTCCTTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentaxoncomponentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentintegral component of synaptic vesicle membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessneurotransmitter transportprocessregulation of membrane potentialprocessregulation of neurotransmitter levelsprocessresponse to drugprocesssynaptic transmissionprocesstransmembrane transport
name:Gamma-aminobutyric acid receptor subunit alpha-3
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA3
locus:Xq28
cellular-location:Cell junction
transmembrane-regions:277-298 304-325 338-359 458-479
signal-regions:1-28
theoretical-pi:8.93
molecular-weight:55164.055
chromosome-location:X
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4077GenAtlasGABRA3GenBank Gene DatabaseS62908GenBank Protein Database386424IUPHAR406Guide to Pharmacology406UniProtKBP34903UniProt AccessionGBRA3_HUMAN
synonyms:GABA(A) receptor subunit alpha-3
amino-acid-sequence:>lcl|BSEQ0016119|Gamma-aminobutyric acid receptor subunit alpha-3 MIITQTSHCYMTSLGILFLINILPGTTGQGESRRQEPGDFVKQDIGGLSPKHAPDIPDDS TDNITIFTRILDRLLDGYDNRLRPGLGDAVTEVKTDIYVTSFGPVSDTDMEYTIDVFFRQ TWHDERLKFDGPMKILPLNNLLASKIWTPDTFFHNGKKSVAHNMTTPNKLLRLVDNGTLL YTMRLTIHAECPMHLEDFPMDVHACPLKFGSYAYTTAEVVYSWTLGKNKSVEVAQDGSRL NQYDLLGHVVGTEIIRSSTGEYVVMTTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLN RESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVN YFTKRSWAWEGKKVPEALEMKKKTPAAPAKKTSTTFNIVGTTYPINLAKDTEFSTISKGA APSASSTPTIIASPKATYVQDSPTETKTYNSVSKVDKISRIIFPVLFAIFNLVYWATYVN RESAIKGMIRKQ
gene-sequence:>lcl|BSEQ0016120|Gamma-aminobutyric acid receptor subunit alpha-3 (GABRA3) ATGATAATCACACAAACAAGTCACTGTTACATGACCAGCCTTGGGATTCTTTTCCTGATT AATATTCTCCCTGGAACCACTGGTCAAGGGGAATCAAGACGACAAGAACCCGGGGACTTT GTGAAGCAGGACATTGGCGGGCTGTCTCCTAAGCATGCCCCAGATATTCCTGATGACAGC ACTGACAACATCACTATCTTCACCAGAATCTTGGATCGTCTTCTGGACGGCTATGACAAC CGGCTGCGACCTGGGCTTGGAGATGCAGTGACTGAAGTGAAGACTGACATCTACGTGACC AGTTTTGGCCCTGTGTCAGACACTGACATGGAGTACACTATTGATGTATTTTTTCGGCAG ACATGGCATGATGAAAGACTGAAATTTGATGGCCCCATGAAGATCCTTCCACTGAACAAT CTCCTGGCTAGTAAGATCTGGACACCGGACACCTTCTTCCACAATGGCAAGAAATCAGTG GCTCATAACATGACCACGCCCAACAAGCTGCTCAGATTGGTGGACAACGGAACCCTCCTC TATACAATGAGGTTAACAATTCATGCTGAGTGTCCCATGCATTTGGAAGATTTTCCCATG GATGTGCATGCCTGCCCACTGAAGTTTGGAAGCTATGCCTATACAACAGCTGAAGTGGTT TATTCTTGGACTCTCGGAAAGAACAAATCCGTGGAAGTGGCACAGGATGGTTCTCGCTTG AACCAGTATGACCTTTTGGGCCATGTTGTTGGGACAGAGATAATCCGGTCTAGTACAGGA GAATATGTCGTCATGACAACCCACTTCCATCTCAAGCGAAAAATTGGCTACTTTGTGATC CAGACCTACTTGCCATGTATCATGACTGTCATTCTGTCACAAGTGTCGTTCTGGCTCAAC AGAGAGTCTGTTCCTGCCCGTACAGTCTTTGGTGTCACCACTGTGCTTACCATGACCACC TTGAGTATCAGTGCCAGAAATTCCTTACCTAAAGTGGCATATGCGACGGCCATGGACTGG TTCATAGCCGTCTGTTATGCCTTTGTATTTTCTGCACTGATTGAATTTGCCACTGTCAAC TATTTCACCAAGCGGAGTTGGGCTTGGGAAGGCAAGAAGGTGCCAGAGGCCCTGGAGATG AAGAAGAAAACACCAGCAGCCCCAGCAAAGAAAACCAGCACTACCTTCAACATCGTGGGG ACCACCTATCCCATCAACCTGGCCAAGGACACTGAATTTTCCACCATCTCCAAGGGCGCT GCTCCCAGTGCCTCCTCAACCCCAACAATCATTGCTTCACCCAAGGCCACCTACGTGCAG GACAGCCCGACTGAGACCAAGACCTACAACAGTGTCAGCAAGGTTGACAAAATTTCCCGC ATCATCTTTCCTGTGCTCTTTGCCATATTCAATCTGGTCTATTGGGCCACATATGTCAAC CGGGAGTCAGCTATCAAGGGCATGATCCGCAAACAGTAG
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit alpha-4
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA4
locus:4p12
cellular-location:Cell junction
transmembrane-regions:259-280 285-306 318-340 524-543
signal-regions:1-35
theoretical-pi:10.0
molecular-weight:61622.645
chromosome-location:4
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4078GenAtlasGABRA4GenBank Gene DatabaseU30461GenBank Protein Database905393IUPHAR407UniProtKBP48169UniProt AccessionGBRA4_HUMAN
synonyms:GABA(A) receptor subunit alpha-4
amino-acid-sequence:>lcl|BSEQ0018959|Gamma-aminobutyric acid receptor subunit alpha-4 MVSAKKVPAIALSAGVSFALLRFLCLAVCLNESPGQNQKEEKLCTENFTRILDSLLDGYD NRLRPGFGGPVTEVKTDIYVTSFGPVSDVEMEYTMDVFFRQTWIDKRLKYDGPIEILRLN NMMVTKVWTPDTFFRNGKKSVSHNMTAPNKLFRIMRNGTILYTMRLTISAECPMRLVDFP MDGHACPLKFGSYAYPKSEMIYTWTKGPEKSVEVPKESSSLVQYDLIGQTVSSETIKSIT GEYIVMTVYFHLRRKMGYFMIQTYIPCIMTVILSQVSFWINKESVPARTVFGITTVLTMT TLSISARHSLPKVSYATAMDWFIAVCFAFVFSALIEFAAVNYFTNIQMEKAKRKTSKPPQ EVPAAPVQREKHPEAPLQNTNANLNMRKRTNALVHSESDVGNRTEVGNHSSKSSTVVQES SKGTPRSYLASSPNPFSRANAAETISAARALPSASPTSIRTGYMPRKASVGSASTRHVFG SRLQRIKTTVNTIGATGKLSATPPPSAPPPSGSGTSKIDKYARILFPVTFGAFNMVYWVV YLSKDTMEKSESLM
gene-sequence:>lcl|BSEQ0018960|Gamma-aminobutyric acid receptor subunit alpha-4 (GABRA4) ATGGTTTCTGCCAAGAAGGTACCCGCGATCGCTCTGTCCGCCGGGGTCAGTTTCGCCCTC CTGCGCTTCCTGTGCCTGGCGGTTTGTTTAAACGAATCCCCAGGACAGAACCAAAAGGAG GAGAAATTGTGCACAGAAAATTTCACCCGCATCCTGGACAGTTTGCTCGATGGTTATGAC AACAGGCTGCGTCCTGGATTTGGGGGTCCTGTTACAGAAGTGAAAACTGACATATATGTC ACCAGCTTTGGACCTGTTTCTGATGTTGAAATGGAATACACAATGGATGTGTTCTTCAGG CAGACATGGATTGACAAAAGATTAAAATATGACGGCCCCATTGAAATTTTGAGATTGAAC AATATGATGGTAACGAAAGTGTGGACCCCTGATACTTTCTTCAGGAATGGAAAGAAATCT GTCTCACATAATATGACAGCTCCAAATAAGCTTTTTAGAATTATGAGAAATGGTACTATT TTATACACAATGAGACTCACCATAAGTGCGGAGTGTCCCATGAGATTGGTGGATTTTCCC ATGGATGGTCATGCATGCCCTTTGAAATTCGGGAGTTATGCCTATCCAAAGAGTGAGATG ATCTATACCTGGACAAAAGGTCCTGAGAAATCAGTTGAAGTTCCGAAGGAGTCTTCCAGC TTAGTTCAATATGATTTGATTGGGCAAACCGTATCAAGTGAAACCATCAAATCAATTACG GGTGAATATATTGTTATGACGGTTTACTTCCACCTCAGACGGAAGATGGGTTATTTTATG ATTCAGACCTATATTCCGTGCATTATGACAGTGATTCTTTCTCAAGTTTCATTTTGGATA AATAAAGAATCAGTTCCCGCTAGGACTGTATTTGGAATAACAACTGTCCTCACCATGACC ACACTAAGCATCAGTGCACGACATTCTTTGCCCAAAGTGTCCTATGCTACCGCCATGGAC TGGTTCATAGCTGTCTGCTTTGCTTTTGTATTTTCGGCCCTTATCGAGTTTGCTGCTGTC AACTATTTCACCAATATTCAAATGGAAAAAGCCAAAAGGAAGACATCAAAGCCCCCTCAG GAAGTTCCCGCTGCTCCAGTGCAGAGAGAGAAGCATCCTGAAGCCCCTCTGCAGAATACA AATGCCAATTTGAACATGAGAAAAAGAACAAATGCTTTGGTTCACTCTGAATCTGATGTT GGCAACAGAACTGAGGTGGGAAACCATTCAAGCAAATCTTCCACAGTTGTTCAAGAATCT TCTAAAGGCACACCTCGGTCTTACTTAGCTTCCAGTCCAAACCCATTCAGCCGTGCAAAT GCAGCTGAAACCATATCTGCAGCAAGAGCACTTCCATCTGCTTCTCCTACTTCTATCCGA ACTGGATATATGCCTCGAAAGGCTTCAGTTGGATCTGCTTCTACTCGTCACGTGTTTGGA TCAAGACTGCAGAGGATAAAGACCACAGTTAATACCATAGGGGCTACTGGGAAGTTGTCA GCTACTCCTCCTCCATCGGCTCCACCACCTTCTGGATCTGGCACAAGTAAAATAGACAAA TATGCCCGTATTCTCTTTCCAGTCACATTTGGGGCATTTAACATGGTTTATTGGGTTGTT TATTTATCTAAGGACACTATGGAGAAATCAGAAAGTCTAATGTAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesscentral nervous system developmentprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessregulation of response to drugprocessresponse to drugprocesssynaptic transmissionprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit alpha-5
general-function:Transporter activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA5
locus:15q11.2-q12
cellular-location:Cell junction
transmembrane-regions:260-281 286-307 319-341 428-449
signal-regions:1-31
theoretical-pi:9.56
molecular-weight:52145.645
chromosome-location:15
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4079GenAtlasGABRA5GenBank Gene DatabaseL08485GenBank Protein Database182916IUPHAR408Guide to Pharmacology408UniProtKBP31644UniProt AccessionGBRA5_HUMAN
synonyms:GABA(A) receptor subunit alpha-5
amino-acid-sequence:>lcl|BSEQ0010331|Gamma-aminobutyric acid receptor subunit alpha-5 MDNGMFSGFIMIKNLLLFCISMNLSSHFGFSQMPTSSVKDETNDNITIFTRILDGLLDGY DNRLRPGLGERITQVRTDIYVTSFGPVSDTEMEYTIDVFFRQSWKDERLRFKGPMQRLPL NNLLASKIWTPDTFFHNGKKSIAHNMTTPNKLLRLEDDGTLLYTMRLTISAECPMQLEDF PMDAHACPLKFGSYAYPNSEVVYVWTNGSTKSVVVAEDGSRLNQYHLMGQTVGTENISTS TGEYTIMTAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTM TTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKKALEAA KIKKKREVILNKSTNAFTTGKMSHPPNIPKEQTPAGTSNTTSVSVKPSEEKTSESKKTYN SISKIDKMSRIVFPVLFGTFNLVYWATYLNREPVIKGAASPK
gene-sequence:>lcl|BSEQ0010332|Gamma-aminobutyric acid receptor subunit alpha-5 (GABRA5) ATGGACAATGGAATGTTCTCTGGTTTTATCATGATCAAAAACCTCCTTCTCTTTTGTATT TCCATGAACTTATCCAGTCACTTTGGCTTTTCACAGATGCCAACCAGTTCAGTGAAAGAT GAGACCAATGACAACATCACGATATTTACCAGGATCTTGGATGGGCTCTTGGATGGCTAC GACAACAGACTTCGGCCCGGGCTGGGAGAGCGCATCACTCAGGTGAGGACCGACATCTAC GTCACCAGCTTCGGCCCGGTGTCCGACACGGAAATGGAGTACACCATAGACGTGTTTTTC CGACAAAGCTGGAAAGATGAAAGGCTTCGGTTTAAGGGGCCCATGCAGCGCCTCCCTCTC AACAACCTCCTTGCCAGCAAGATCTGGACCCCAGACACGTTCTTCCACAACGGGAAGAAG TCCATCGCTCACAACATGACCACGCCCAACAAGCTGCTGCGGCTGGAGGACGACGGCACC CTGCTCTACACCATGCGCTTGACCATCTCTGCAGAGTGCCCCATGCAGCTTGAGGACTTC CCGATGGATGCGCACGCTTGCCCTCTGAAATTTGGCAGCTATGCGTACCCTAATTCTGAA GTCGTTTACGTCTGGACCAACGGCTCCACCAAGTCGGTGGTGGTGGCGGAAGATGGCTCC AGACTGAACCAGTACCACCTGATGGGGCAGACGGTGGGCACTGAGAACATCAGCACCAGC ACAGGCGAATACACAATCATGACAGCTCACTTCCACCTGAAAAGGAAGATTGGCTACTTT GTCATCCAGACCTACCTTCCCTGCATAATGACCGTGATCTTATCACAGGTGTCCTTTTGG CTGAACCGGGAATCAGTCCCAGCCAGGACAGTTTTTGGGGTCACCACGGTGCTGACCATG ACGACCCTCAGCATCAGCGCCAGGAACTCTCTGCCCAAAGTGGCCTACGCCACCGCCATG GACTGGTTCATAGCCGTGTGCTATGCCTTCGTCTTCTCGGCGCTGATAGAGTTTGCCACG GTCAATTACTTTACCAAGAGAGGCTGGGCCTGGGATGGCAAAAAAGCCTTGGAAGCAGCC AAGATCAAGAAAAAGCGTGAAGTCATACTAAATAAGTCAACAAACGCTTTTACAACTGGG AAGATGTCTCACCCCCCAAACATTCCGAAGGAACAGACCCCAGCAGGGACGTCGAATACA ACCTCAGTCTCAGTAAAACCCTCTGAAGAGAAGACTTCTGAAAGCAAAAAGACTTACAAC AGTATCAGCAAAATTGACAAAATGTCCCGAATCGTATTCCCAGTCTTGTTCGGCACTTTC AACTTAGTTTACTGGGCAACGTATTTGAATAGGGAGCCGGTGATAAAAGGAGCCGCCTCT CCAAAATAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentdendritecomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentneuronal cell body membranecomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityfunctionreceptor activityfunctiontransporter activityprocessassociative learningprocessbehavioral fear responseprocessbrain developmentprocesschloride transmembrane transportprocesscochlea developmentprocessgamma-aminobutyric acid signaling pathwayprocessinner ear receptor cell developmentprocessinnervationprocession transmembrane transportprocessmitophagy in response to mitochondrial depolarizationprocessnegative regulation of neuron apoptotic processprocessneurological system processprocesspositive regulation of defense response to virus by hostprocessregulation of membrane potentialprocessresponse to drugprocesssensory perception of soundprocesssignal transductionprocesssynaptic transmissionprocesstransmembrane transportprocesstransportprocessxenophagy
name:Gamma-aminobutyric acid receptor subunit alpha-6
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA6
locus:5q34
cellular-location:Cell junction
transmembrane-regions:243-264 269-290 301-324 420-441
signal-regions:1-19
theoretical-pi:8.4
molecular-weight:51023.69
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4080GenAtlasGABRA6GenBank Gene DatabaseS81944GenBank Protein Database1470364IUPHAR409Guide to Pharmacology409UniProtKBQ16445UniProt AccessionGBRA6_HUMAN
synonyms:GABA(A) receptor subunit alpha-6
amino-acid-sequence:>lcl|BSEQ0010540|Gamma-aminobutyric acid receptor subunit alpha-6 MASSLPWLCIILWLENALGKLEVEGNFYSENVSRILDNLLEGYDNRLRPGFGGAVTEVKT DIYVTSFGPVSDVEMEYTMDVFFRQTWTDERLKFGGPTEILSLNNLMVSKIWTPDTFFRN GKKSIAHNMTTPNKLFRIMQNGTILYTMRLTINADCPMRLVNFPMDGHACPLKFGSYAYP KSEIIYTWKKGPLYSVEVPEESSSLLQYDLIGQTVSSETIKSNTGEYVIMTVYFHLQRKM GYFMIQIYTPCIMTVILSQVSFWINKESVPARTVFGITTVLTMTTLSISARHSLPKVSYA TAMDWFIAVCFAFVFSALIEFAAVNYFTNLQTQKAKRKAQFAAPPTVTISKATEPLEAEI VLHPDSKYHLKKRITSLSLPIVSSSEANKVLTRAPILQSTPVTPPPLSPAFGGTSKIDQY SRILFPVAFAGFNLVYWVVYLSKDTMEVSSSVE
gene-sequence:>lcl|BSEQ0010541|Gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6) ATGGCGTCGTCTCTGCCCTGGCTGTGCATTATTCTGTGGCTAGAAAATGCCCTAGGGAAA CTCGAAGTTGAAGGCAACTTCTACTCAGAAAACGTCAGTCGGATCCTGGACAACTTGCTT GAAGGCTATGACAATCGGCTGCGGCCGGGATTTGGAGGTGCTGTCACTGAAGTCAAAACA GACATTTATGTGACCAGTTTTGGGCCCGTGTCAGATGTGGAGATGGAGTATACGATGGAT GTTTTTTTCCGCCAGACCTGGACTGATGAGAGGTTGAAGTTTGGGGGGCCAACTGAGATT CTGAGTCTGAATAATTTGATGGTCAGTAAAATCTGGACGCCTGACACCTTTTTCAGAAAT GGTAAAAAGTCCATTGCTCACAACATGACAACTCCTAATAAACTCTTCAGAATAATGCAG AATGGAACCATTTTATACACCATGAGGCTTACCATCAATGCTGACTGTCCCATGAGGCTG GTTAACTTTCCTATGGATGGGCATGCTTGTCCACTCAAGTTTGGGAGCTATGCTTATCCC AAAAGTGAAATCATATATACGTGGAAAAAAGGACCACTTTACTCAGTAGAAGTCCCAGAA GAATCTTCAAGCCTTCTCCAGTATGATCTGATTGGACAAACAGTATCTAGTGAGACAATT AAATCTAACACAGGTGAATACGTTATAATGACAGTTTACTTCCACTTGCAAAGGAAGATG GGCTACTTCATGATACAGATATACACTCCTTGCATTATGACAGTCATTCTTTCCCAGGTG TCTTTCTGGATTAATAAGGAGTCCGTCCCAGCAAGAACTGTTTTTGGGATCACCACTGTT TTAACTATGACCACTTTGAGCATCAGTGCCCGGCACTCTTTGCCAAAAGTGTCATATGCC ACTGCCATGGATTGGTTCATAGCTGTTTGCTTTGCATTCGTCTTCTCTGCGCTTATCGAG TTCGCAGCTGTCAACTACTTTACCAATCTTCAGACACAGAAGGCCAAAAGGAAGGCACAG TTTGCAGCCCCACCCACAGTGACAATATCAAAAGCTACTGAACCTTTGGAAGCTGAGATT GTTTTGCATCCTGACTCCAAATATCATCTGAAGAAAAGGATCACTTCTCTGTCTTTGCCA ATAGTTTCATCTTCCGAGGCCAATAAAGTGCTCACGAGAGCGCCCATCTTACAATCAACA CCTGTCACACCCCCACCACTCTCGCCAGCCTTTGGAGGCACCAGTAAAATAGACCAGTAT TCTCGAATTCTCTTCCCAGTTGCATTTGCAGGATTCAACCTTGTGTACTGGGTAGTTTAT CTTTCCAAAGATACAATGGAAGTCAGTAGCAGTGTTGAATAG
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssignal transductionprocesssynaptic transmissionprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit beta-1
general-function:Ligand-gated ion channel activity
specific-function:Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
gene-name:GABRB1
locus:4p12
cellular-location:Cell junction
transmembrane-regions:246-267 271-293 305-327 452-473
signal-regions:1-25
theoretical-pi:9.01
molecular-weight:54234.085
chromosome-location:4
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4081GenAtlasGABRB1GenBank Gene DatabaseX14767GenBank Protein Database31635IUPHAR410UniProtKBP18505UniProt AccessionGBRB1_HUMAN
synonyms:GABA(A) receptor subunit beta-1
amino-acid-sequence:>lcl|BSEQ0004603|Gamma-aminobutyric acid receptor subunit beta-1 MWTVQNRESLGLLSFPVMITMVCCAHSTNEPSNMSYVKETVDRLLKGYDIRLRPDFGGPP VDVGMRIDVASIDMVSEVNMDYTLTMYFQQSWKDKRLSYSGIPLNLTLDNRVADQLWVPD TYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIE SYGYTTDDIEFYWNGGEGAVTGVNKIELPQFSIVDYKMVSKKVEFTTGAYPRLSLSFRLK RNIGYFILQTYMPSTLITILSWVSFWINYDASAARVALGITTVLTMTTISTHLRETLPKI PYVKAIDIYLMGCFVFVFLALLEYAFVNYIFFGKGPQKKGASKQDQSANEKNKLEMNKVQ VDAHGNILLSTLEIRNETSGSEVLTSVSDPKATMYSYDSASIQYRKPLSSREAYGRALDR HGVPSKGRIRRRASQLKVKIPDLTDVNSIDKWSRMFFPITFSLFNVVYWLYYVH
gene-sequence:>lcl|BSEQ0020610|Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1) ATGTGGACAGTACAAAATCGAGAGAGTCTGGGGCTTCTCTCTTTCCCTGTGATGATTACC ATGGTCTGTTGTGCACACAGCACCAATGAACCCAGCAACATGTCATACGTGAAAGAGACA GTGGACAGATTGCTCAAAGGATATGACATTCGCTTGCGGCCGGACTTCGGAGGGCCCCCC GTCGACGTTGGGATGCGGATCGATGTCGCCAGCATAGACATGGTCTCCGAAGTGAATATG GATTATACACTCACCATGTATTTCCAGCAGTCTTGGAAAGACAAAAGGCTTTCTTATTCT GGAATCCCACTGAACCTCACCCTAGACAATAGGGTAGCTGACCAACTCTGGGTACCAGAC ACCTACTTTCTGAATGACAAGAAATCATTTGTGCATGGGGTCACAGTGAAAAATCGAATG ATTCGACTGCATCCTGATGGAACAGTTCTCTATGGACTCCGAATCACAACCACAGCTGCA TGTATGATGGATCTTCGAAGATATCCACTGGATGAGCAGAACTGCACCCTGGAGATCGAA AGTTATGGCTATACCACTGATGACATTGAATTTTACTGGAATGGAGGAGAAGGGGCAGTC ACTGGTGTTAATAAAATCGAACTTCCTCAATTTTCAATTGTTGACTACAAGATGGTGTCT AAGAAGGTGGAGTTCACAACAGGAGCGTATCCACGACTGTCACTAAGTTTTCGTCTAAAG AGAAACATTGGTTACTTCATTTTGCAAACCTACATGCCTTCTACACTGATTACAATTCTG TCCTGGGTGTCTTTTTGGATCAACTATGATGCATCTGCAGCCAGAGTCGCACTAGGAATC ACGACAGTGCTTACAATGACAACCATCAGCACCCACCTCAGGGAGACCCTGCCAAAGATC CCTTATGTCAAAGCGATTGATATTTATCTGATGGGTTGCTTTGTGTTTGTGTTCCTGGCT CTGCTGGAGTATGCCTTTGTAAATTACATCTTCTTTGGGAAAGGCCCTCAGAAAAAGGGA GCTAGCAAACAAGACCAGAGTGCCAATGAGAAGAATAAACTGGAGATGAATAAAGTCCAG GTCGACGCCCACGGTAACATTCTCCTCAGCACCCTGGAAATCCGGAATGAGACGAGTGGC TCGGAAGTGCTCACGAGCGTGAGCGACCCCAAGGCCACCATGTACTCCTATGACAGCGCC AGCATCCAGTACCGCAAGCCCCTGAGCAGCCGCGAGGCCTACGGGCGCGCCCTGGACCGG CACGGGGTACCCAGCAAGGGGCGCATCCGCAGGCGTGCCTCCCAGCTCAAAGTCAAGATC CCCGACTTGACTGATGTGAATTCCATAGACAAGTGGTCCCGAATGTTTTTCCCCATCACC TTTTCTCTTTTTAATGTCGTCTATTGGCTTTACTATGTACACTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentcytoplasmcomponentdendritecomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentnuclear envelopecomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionextracellular ligand-gated ion channel activityfunctionGABA-A receptor activityfunctionligand-gated ion channel activityprocesscellular response to histamineprocesscentral nervous system neuron developmentprocesschloride transmembrane transportprocession transmembrane transportprocession transportprocessneurological system processprocessovulation cycleprocessregulation of membrane potentialprocessresponse to progesteroneprocessresponse to toxic substanceprocesssignal transductionprocesssynaptic transmissionprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit beta-2
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
gene-name:GABRB2
locus:5q34
cellular-location:Cell junction
transmembrane-regions:245-266 270-292 304-326 490-511
signal-regions:1-25
theoretical-pi:9.66
molecular-weight:59149.895
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4082GenAtlasGABRB2GenBank Gene DatabaseS67368GenBank Protein Database455946IUPHAR411UniProtKBP47870UniProt AccessionGBRB2_HUMAN
synonyms:GABA(A) receptor subunit beta-2
amino-acid-sequence:>lcl|BSEQ0037195|Gamma-aminobutyric acid receptor subunit beta-2 MWRVRKRGYFGIWSFPLIIAAVCAQSVNDPSNMSLVKETVDRLLKGYDIRLRPDFGGPPV AVGMNIDIASIDMVSEVNMDYTLTMYFQQAWRDKRLSYNVIPLNLTLDNRVADQLWVPDT YFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIES YGYTTDDIEFYWRGDDNAVTGVTKIELPQFSIVDYKLITKKVVFSTGSYPRLSLSFKLKR NIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKIP YVKAIDMYLMGCFVFVFMALLEYALVNYIFFGRGPQRQKKAAEKAASANNEKMRLDVNKI FYKDIKQNGTQYRSLWDPTGNLSPTRRTTNYDFSLYTMDPHENILLSTLEIKNEMATSEA VMGLGDPRSTMLAYDASSIQYRKAGLPRHSFGRNALERHVAQKKSRLRRRASQLKITIPD LTDVNAIDRWSRIFFPVVFSFFNIVYWLYYVN
gene-sequence:>lcl|BSEQ0011685|Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2) ATGTGGAGAGTGCGGAAAAGGGGCTACTTTGGGATTTGGTCCTTCCCCTTAATAATCGCC GCTGTCTGTGCGCAGAGTGTCAATGACCCTAGTAATATGTCGCTGGTTAAAGAGACGGTG GATAGACTCCTGAAAGGCTATGACATTCGTCTGAGACCAGATTTTGGAGGTCCCCCCGTG GCTGTGGGGATGAACATTGACATTGCCAGCATCGATATGGTTTCTGAAGTCAATATGGAT TATACCTTGACAATGTACTTTCAACAAGCCTGGAGAGATAAGAGGCTGTCCTATAATGTA ATACCTTTAAACTTGACTCTGGACAACAGAGTGGCAGACCAGCTCTGGGTGCCTGATACC TATTTCCTGAACGATAAGAAGTCATTTGTGCACGGAGTGACTGTTAAGAACCGCATGATT CGCCTGCATCCTGATGGCACCGTCCTTTATGGACTCAGAATCACAACCACAGCTGCCTGC ATGATGGACCTAAGGAGGTACCCACTGGATGAACAAAACTGCACCTTGGAAATTGAGAGC TATGGATACACAACTGATGACATTGAGTTTTACTGGCGTGGCGATGATAATGCAGTAACA GGAGTAACGAAAATTGAACTTCCACAGTTCTCTATTGTAGATTACAAACTTATCACCAAG AAGGTTGTTTTTTCCACAGGTTCCTATCCCAGGTTATCCCTCAGCTTTAAGCTTAAGAGA AACATTGGCTACTTTATCCTGCAAACATACATGCCTTCCATCCTGATTACCATCCTCTCC TGGGTCTCCTTCTGGATTAATTACGATGCTTCAGCTGCAAGGGTGGCATTAGGAATCACA ACTGTCCTCACAATGACCACAATCAACACCCACCTCCGGGAAACTCTCCCTAAAATCCCC TATGTGAAGGCCATTGACATGTACCTGATGGGGTGCTTTGTCTTCGTTTTCATGGCCCTT CTGGAATATGCCCTAGTCAACTACATCTTCTTTGGGAGGGGGCCCCAACGCCAAAAGAAA GCAGCTGAGAAGGCTGCCAGTGCCAACAATGAGAAGATGCGCCTGGATGTCAACAAGATG GACCCCCATGAGAACATCTTACTGAGCACTCTCGAGATAAAAAATGAAATGGCCACATCT GAGGCTGTGATGGGACTTGGAGACCCCAGAAGCACAATGCTAGCCTATGATGCCTCCAGC ATCCAGTATCGGAAAGCTGGGTTGCCCAGGCATAGTTTTGGCCGAAATGCTCTGGAACGA CATGTGGCGCAAAAGAAAAGTCGCCTGAGGAGACGCGCCTCCCAACTGAAAATCACCATC CCTGACTTGACTGATGTGAATGCCATAGATCGGTGGTCCCGCATATTCTTCCCAGTGGTT TTTTCCTTCTTCAACATCGTCTATTGGCTTTATTATGTGAACTAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentcytosolcomponentextracellular exosomecomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesscellular response to histamineprocesschloride transmembrane transportprocesscochlea developmentprocessgamma-aminobutyric acid signaling pathwayprocessinner ear receptor cell developmentprocessinnervationprocession transmembrane transportprocessnegative regulation of neuron apoptotic processprocessneurological system processprocessregulation of membrane potentialprocesssensory perception of soundprocesssynaptic transmissionprocesssynaptic transmission, GABAergicprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit beta-3
general-function:Gaba-gated chloride ion channel activity
specific-function:Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
gene-name:GABRB3
locus:15q11.2-q12
cellular-location:Cell junction
transmembrane-regions:246-267 271-293 305-327 451-472
signal-regions:1-25
theoretical-pi:9.41
molecular-weight:54115.04
chromosome-location:15
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4083GenAtlasGABRB3GenBank Gene DatabaseM82919GenBank Protein Database182925IUPHAR412Guide to Pharmacology412UniProtKBP28472UniProt AccessionGBRB3_HUMAN
synonyms:GABA(A) receptor subunit beta-3
amino-acid-sequence:>lcl|BSEQ0004605|Gamma-aminobutyric acid receptor subunit beta-3 MWGLAGGRLFGIFSAPVLVAVVCCAQSVNDPGNMSFVKETVDKLLKGYDIRLRPDFGGPP VCVGMNIDIASIDMVSEVNMDYTLTMYFQQYWRDKRLAYSGIPLNLTLDNRVADQLWVPD TYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIE SYGYTTDDIEFYWRGGDKAVTGVERIELPQFSIVEHRLVSRNVVFATGAYPRLSLSFRLK RNIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKI PYVKAIDMYLMGCFVFVFLALLEYAFVNYIFFGRGPQRQKKLAEKTAKAKNDRSKSESNR VDAHGNILLTSLEVHNEMNEVSGGIGDTRNSAISFDNSGIQYRKQSMPREGHGRFLGDRS LPHKKTHLRRRSSQLKIKIPDLTDVNAIDRWSRIVFPFTFSLFNLVYWLYYVN
gene-sequence:>lcl|BSEQ0016761|Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3) ATGTGGGGCCTTGCGGGAGGAAGGCTTTTCGGCATCTTCTCGGCCCCGGTGCTGGTGGCT GTGGTGTGCTGCGCCCAGAGTGTGAACGATCCCGGGAACATGTCCTTTGTGAAGGAGACG GTGGACAAGCTGTTGAAAGGCTACGACATTCGCCTAAGACCCGACTTCGGGGGTCCCCCG GTCTGCGTGGGGATGAACATCGACATCGCCAGCATCGACATGGTTTCCGAAGTCAACATG GATTATACCTTAACCATGTATTTTCAACAATATTGGAGAGATAAAAGGCTCGCCTATTCT GGGATCCCTCTCAACCTCACGCTTGACAATCGAGTGGCTGACCAGCTATGGGTGCCCGAC ACATATTTCTTAAATGACAAAAAGTCATTTGTGCATGGAGTGACAGTGAAAAACCGCATG ATCCGTCTTCACCCTGATGGGACAGTGCTGTATGGGCTCAGAATCACCACGACAGCAGCA TGCATGATGGACCTCAGGAGATACCCCCTGGACGAGCAGAACTGCACTCTGGAAATTGAA AGCTATGGCTACACCACGGATGACATTGAGTTTTACTGGCGAGGCGGGGACAAGGCTGTT ACCGGAGTGGAAAGGATTGAGCTCCCGCAGTTCTCCATCGTGGAGCACCGTCTGGTCTCG AGGAATGTTGTCTTCGCCACAGGTGCCTATCCTCGACTGTCACTGAGCTTTCGGTTGAAG AGGAACATTGGATACTTCATTCTTCAGACTTATATGCCCTCTATACTGATAACGATTCTG TCGTGGGTGTCCTTCTGGATCAATTATGATGCATCTGCTGCTAGAGTTGCCCTCGGGATC ACAACTGTGCTGACAATGACAACCATCAACACCCACCTTCGGGAGACCTTGCCCAAAATC CCCTATGTCAAAGCCATTGACATGTACCTTATGGGCTGCTTCGTCTTTGTGTTCCTGGCC CTTCTGGAGTATGCCTTTGTCAACTACATTTTCTTTGGAAGAGGCCCTCAAAGGCAGAAG AAGCTTGCAGAAAAGACAGCCAAGGCAAAGAATGACCGTTCAAAGAGCGAAAGCAACCGG GTGGATGCTCATGGAAATATTCTGTTGACATCGCTGGAAGTTCACAATGAAATGAATGAG GTCTCAGGCGGCATTGGCGATACCAGGAATTCAGCAATATCCTTTGACAACTCAGGAATC CAGTACAGGAAACAGAGCATGCCTCGAGAAGGGCATGGGCGATTCCTGGGGGACAGAAGC CTCCCGCACAAGAAGACCCATCTACGGAGGAGGTCTTCACAGCTCAAAATTAAAATACCT GATCTAACCGATGTGAATGCCATAGACAGATGGTCCAGGATCGTGTTTCCATTCACTTTT TCTCTTTTCAACTTAGTTTACTGGCTGTACTATGTTAACTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionextracellular ligand-gated ion channel activityfunctionGABA-A receptor activityfunctionGABA-gated chloride ion channel activityprocesscellular response to histamineprocesschloride transmembrane transportprocesscochlea developmentprocessinhibitory postsynaptic potentialprocessinner ear receptor cell developmentprocessinnervationprocession transmembrane transportprocessnegative regulation of neuron apoptotic processprocessneurological system processprocesspalate developmentprocessregulation of membrane potentialprocesssensory perception of soundprocesssignal transductionprocesssynaptic transmissionprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit delta
general-function:Gaba-a receptor activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRD
locus:1p|1p36.3
cellular-location:Cell junction
transmembrane-regions:249-271 275-297 309-331 430-452
signal-regions:1-16
theoretical-pi:8.73
molecular-weight:50707.835
chromosome-location:1
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4084GenBank Gene DatabaseAF016917GenBank Protein Database2388693UniProtKBO14764UniProt AccessionGBRD_HUMAN
synonyms:GABA(A) receptor subunit delta
amino-acid-sequence:>lcl|BSEQ0012501|Gamma-aminobutyric acid receptor subunit delta MDAPARLLAPLLLLCAQQLRGTRAMNDIGDYVGSNLEISWLPNLDGLIAGYARNFRPGIG GPPVNVALALEVASIDHISEANMEYTMTVFLHQSWRDSRLSYNHTNETLGLDSRFVDKLW LPDTFIVNAKSAWFHDVTVENKLIRLQPDGVILYSIRITSTVACDMDLAKYPMDEQECML DLESYGYSSEDIVYYWSESQEHIHGLDKLQLAQFTITSYRFTTELMNFKSAGQFPRLSLH FHLRRNRGVYIIQSYMPSVLLVAMSWVSFWISQAAVPARVSLGITTVLTMTTLMVSARSS LPRASAIKALDVYFWICYVFVFAALVEYAFAHFNADYRKKQKAKVKVSRPRAEMDVRNAI VLFSLSAAGVTQELAISRRQRRVPGNLMGSYRSVGVETGETKKEGAARSGGQGGIRARLR PIDADTIDIYARAVFPAAFAAVNVIYWAAYAM
gene-sequence:>lcl|BSEQ0012502|Gamma-aminobutyric acid receptor subunit delta (GABRD) ATGGACGCGCCCGCCCGGCTGCTGGCCCCGCTCCTGCTCCTCTGCGCGCAGCAGCTCCGC GGCACCAGAGCGATGAATGACATCGGCGACTACGTGGGCTCCAACCTGGAGATCTCCTGG CTCCCCAACCTGGACGGGCTGATAGCCGGCTACGCCCGCAACTTCCGGCCTGGCATCGGA GGCCCCCCCGTGAATGTGGCCCTTGCCCTGGAGGTGGCCAGCATCGACCACATCTCAGAG GCCAACATGGAGTACACCATGACGGTGTTCCTGCACCAGAGCTGGCGGGACAGCAGGCTC TCCTACAACCACACCAACGAGACCCTGGGTCTGGACAGCCGCTTCGTGGACAAGCTGTGG CTGCCCGACACCTTCATCGTGAACGCCAAGTCGGCCTGGTTCCACGACGTGACGGTGGAG AACAAGCTCATCCGGCTGCAGCCCGACGGCGTGATCCTGTACAGCATCCGAATCACCTCC ACTGTGGCCTGCGACATGGACCTGGCCAAATACCCCATGGACGAGCAGGAGTGCATGCTG GACCTGGAGAGCTACGGTTACTCATCGGAGGACATCGTCTACTACTGGTCGGAGAGCCAG GAGCACATCCACGGGCTGGACAAGCTGCAGCTGGCGCAGTTCACCATCACCAGCTACCGC TTCACCACGGAGCTGATGAACTTCAAGTCCGCTGGCCAGTTCCCACGGCTCAGCCTGCAC TTCCACCTGCGGAGGAACCGCGGCGTGTACATCATCCAATCCTACATGCCCTCCGTCCTG CTGGTCGCCATGTCCTGGGTCTCCTTCTGGATCAGCCAGGCGGCGGTGCCCGCCAGGGTG TCTCTAGGCATCACCACGGTGCTGACGATGACCACGCTCATGGTCAGTGCCCGCTCCTCC CTGCCACGGGCATCAGCCATCAAGGCACTGGACGTCTACTTCTGGATCTGCTATGTCTTC GTGTTTGCCGCCCTGGTGGAGTACGCCTTTGCTCATTTCAACGCCGACTACAGGAAGAAG CAGAAGGCCAAGGTCAAGGTCTCCAGGCCGAGGGCAGAGATGGACGTGAGGAACGCCATT GTCCTCTTCTCCCTCTCTGCTGCCGGCGTCACGCAGGAGCTGGCCATCTCCCGCCGGCAG CGCCGCGTCCCGGGGAACCTGATGGGCTCCTACAGGTCGGTGGGGGTGGAGACAGGGGAG ACGAAGAAGGAGGGGGCAGCCCGCTCAGGAGGCCAGGGGGGCATCCGTGCCCGGCTCAGG CCCATCGACGCAGACACCATTGACATTTACGCCCGCGCTGTGTTCCCTGCGGCGTTTGCG GCCGTCAATGTCATCTACTGGGCGGCATACGCCATGTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionextracellular ligand-gated ion channel activityfunctionGABA-A receptor activityprocesschloride transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocesssignal transductionprocesssynaptic transmissionprocesstransport
name:Gamma-aminobutyric acid receptor subunit epsilon
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRE
locus:
cellular-location:Cell junction
transmembrane-regions:254-274 281-301 344-364 486-506
signal-regions:1-22
theoretical-pi:8.09
molecular-weight:57971.175
chromosome-location:X
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4085GenBank Gene DatabaseU66661GenBank Protein Database1857126UniProtKBP78334UniProt AccessionGBRE_HUMAN
synonyms:GABA(A) receptor subunit epsilon
amino-acid-sequence:>lcl|BSEQ0006923|Gamma-aminobutyric acid receptor subunit epsilon MLSKVLPVLLGILLILQSRVEGPQTESKNEASSRDVVYGPQPQPLENQLLSEETKSTETE TGSRVGKLPEASRILNTILSNYDHKLRPGIGEKPTVVTVEISVNSLGPLSILDMEYTIDI IFSQTWYDERLCYNDTFESLVLNGNVVSQLWIPDTFFRNSKRTHEHEITMPNQMVRIYKD GKVLYTIRMTIDAGCSLHMLRFPMDSHSCPLSFSSFSYPENEMIYKWENFKLEINEKNSW KLFQFDFTGVSNKTEIITTPVGDFMVMTIFFNVSRRFGYVAFQNYVPSSVTTMLSWVSFW IKTESAPARTSLGITSVLTMTTLGTFSRKNFPRVSYITALDFYIAICFVFCFCALLEFAV LNFLIYNQTKAHASPKLRHPRINSRAHARTRARSRACARQHQEAFVCQIVTTEGSDGEER PSCSAQQPPSPGSPEGPRSLCSKLACCEWCKRFKKYFCMVPDCEGSTWQQGRLCIHVYRL DNYSRVVFPVTFFFFNVLYWLVCLNL
gene-sequence:>lcl|BSEQ0020703|Gamma-aminobutyric acid receptor subunit epsilon (GABRE) ATGTTGTCCAAAGTTCTTCCAGTCCTCCTAGGCATCTTATTGATCCTCCAGTCGAGGGTC GAGGGACCTCAGACTGAATCAAAGAATGAAGCCTCTTCCCGTGATGTTGTCTATGGCCCC CAGCCCCAGCCTCTGGAAAATCAGCTCCTCTCTGAGGAAACAAAGTCAACTGAGACTGAG ACTGGGAGCAGAGTTGGCAAACTGCCAGAAGCCTCTCGCATCCTGAACACTATCCTGAGT AATTATGACCACAAACTGCGCCCTGGCATTGGAGAGAAGCCCACTGTGGTCACTGTTGAG ATCTCCGTCAACAGCCTTGGTCCTCTCTCTATCCTAGACATGGAATACACCATTGACATC ATCTTCTCCCAGACCTGGTACGACGAACGCCTCTGTTACAACGACACCTTTGAGTCTCTT GTTCTGAATGGCAATGTGGTGAGCCAGCTATGGATCCCGGACACCTTTTTTAGGAATTCT AAGAGGACCCACGAGCATGAGATCACCATGCCCAACCAGATGGTCCGCATCTACAAGGAT GGCAAGGTGTTGTACACAATTAGGATGACCATTGATGCCGGATGCTCACTCCACATGCTC AGATTTCCAATGGATTCTCACTCTTGCCCTCTATCTTTCTCTAGCTTTTCCTATCCTGAG AATGAGATGATCTACAAGTGGGAAAATTTCAAGCTTGAAATCAATGAGAAGAACTCCTGG AAGCTCTTCCAGTTTGATTTTACAGGAGTGAGCAACAAAACTGAAATAATCACAACCCCA GTTGGTGACTTCATGGTCATGACGATTTTCTTCAATGTGAGCAGGCGGTTTGGCTATGTT GCCTTTCAAAACTATGTCCCTTCTTCCGTGACCACGATGCTCTCCTGGGTTTCCTTTTGG ATCAAGACAGAGTCTGCTCCAGCCCGGACCTCTCTAGGGATCACCTCTGTTCTGACCATG ACCACGTTGGGCACCTTTTCTCGTAAGAATTTCCCGCGTGTCTCCTATATCACAGCCTTG GATTTCTATATCGCCATCTGCTTCGTCTTCTGCTTCTGCGCTCTGTTGGAGTTTGCTGTG CTCAACTTCCTGATCTACAACCAGACAAAAGCCCATGCTTCTCCTAAACTCCGCCATCCT CGTATCAATAGCCGTGCCCATGCCCGTACCCGTGCACGTTCCCGAGCCTGTGCCCGCCAA CATCAGGAAGCTTTTGTGTGCCAGATTGTCACCACTGAGGGAAGTGATGGAGAGGAGCGC CCGTCTTGCTCAGCCCAGCAGCCCCCTAGCCCAGGTAGCCCTGAGGGTCCCCGCAGCCTC TGCTCCAAGCTGGCCTGCTGTGAGTGGTGCAAGCGTTTTAAGAAGTACTTCTGCATGGTC CCCGATTGTGAGGGCAGTACCTGGCAGCAGGGCCGCCTCTGCATCCATGTCTACCGCCTG GATAACTACTCGAGAGTTGTTTTCCCAGTGACTTTCTTCTTCTTCAATGTGCTCTACTGG CTTGTTTGCCTTAACTTGTAG
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesstransport
name:Gamma-aminobutyric acid receptor subunit gamma-1
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRG1
locus:4p12
cellular-location:Cell junction
transmembrane-regions:273-294 299-320 332-354 445-465
signal-regions:1-35
theoretical-pi:8.23
molecular-weight:53594.49
chromosome-location:4
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4086GenBank Gene DatabaseAK122845GenBank Protein Database193783776UniProtKBQ8N1C3UniProt AccessionGBRG1_HUMAN
synonyms:GABA(A) receptor subunit gamma-1
amino-acid-sequence:>lcl|BSEQ0012496|Gamma-aminobutyric acid receptor subunit gamma-1 MGPLKAFLFSPFLLRSQSRGVRLVFLLLTLHLGNCVDKADDEDDEDLTVNKTWVLAPKIH EGDITQILNSLLQGYDNKLRPDIGVRPTVIETDVYVNSIGPVDPINMEYTIDIIFAQTWF DSRLKFNSTMKVLMLNSNMVGKIWIPDTFFRNSRKSDAHWITTPNRLLRIWNDGRVLYTL RLTINAECYLQLHNFPMDEHSCPLEFSSYGYPKNEIEYKWKKPSVEVADPKYWRLYQFAF VGLRNSTEITHTISGDYVIMTIFFDLSRRMGYFTIQTYIPCILTVVLSWVSFWINKDAVP ARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFAALMEYGTLHYFTSN QKGKTATKDRKLKNKASMTPGLHPGSTLIPMNNISVPQEDDYGYQCLEGKDCASFFCCFE DCRTGSWREGRIHIRIAKIDSYSRIFFPTAFALFNLVYWVGYLYL
gene-sequence:>lcl|BSEQ0012497|Gamma-aminobutyric acid receptor subunit gamma-1 (GABRG1) ATGGGTCCTTTGAAAGCTTTTCTCTTCTCCCCTTTTCTTCTGCGGAGTCAAAGTAGAGGG GTGAGGTTGGTCTTCTTGTTACTGACCCTGCATTTGGGAAACTGTGTTGATAAGGCAGAT GATGAAGATGATGAGGATTTAACGGTGAACAAAACCTGGGTCTTGGCCCCAAAAATTCAT GAAGGAGATATCACACAAATTCTGAATTCATTGCTTCAAGGCTATGACAATAAACTTCGT CCAGATATAGGAGTGAGGCCCACAGTAATTGAAACTGATGTTTATGTAAACAGCATTGGA CCAGTTGATCCAATTAATATGGAATATACAATAGATATAATTTTTGCCCAAACCTGGTTT GACAGTCGTTTAAAATTCAATAGTACCATGAAAGTGCTTATGCTTAACAGTAATATGGTT GGAAAAATTTGGATTCCTGACACTTTCTTCAGAAACTCAAGAAAATCTGATGCTCACTGG ATAACAACTCCTAATCGTCTGCTTCGAATTTGGAATGATGGACGAGTTCTGTATACTCTA AGATTGACAATTAATGCAGAATGTTATCTTCAGCTTCATAACTTTCCCATGGATGAACAT TCCTGTCCACTGGAATTTTCAAGCTATGGATACCCTAAAAATGAAATTGAGTATAAGTGG AAAAAGCCCTCCGTAGAAGTGGCTGATCCTAAATACTGGAGATTATATCAGTTTGCATTT GTAGGGTTACGGAACTCAACTGAAATCACTCACACGATCTCTGGGGATTATGTTATCATG ACAATTTTTTTTGACCTGAGCAGAAGAATGGGATATTTCACTATTCAGACCTACATTCCA TGCATTCTGACAGTTGTTCTTTCTTGGGTGTCTTTTTGGATCAATAAAGATGCAGTGCCT GCAAGAACATCGTTGGGTATCACTACAGTTCTGACTATGACAACCCTGAGTACAATTGCC AGGAAGTCTTTACCTAAGGTTTCTTATGTGACTGCGATGGATCTCTTTGTTTCTGTTTGT TTCATTTTTGTTTTTGCAGCCTTGATGGAATATGGAACCTTGCATTATTTTACCAGCAAC CAAAAAGGAAAGACTGCTACTAAAGACAGAAAGCTAAAAAATAAAGCCTCGATGACTCCT GGTCTCCATCCTGGATCCACTCTGATTCCAATGAATAATATTTCTGTGCCGCAAGAAGAT GATTATGGGTATCAGTGTTTGGAGGGCAAAGATTGTGCCAGCTTCTTCTGTTGCTTTGAA GACTGCAGAACAGGATCTTGGAGGGAAGGAAGGATACACATACGCATTGCCAAAATTGAC TCTTATTCTAGAATATTTTTCCCAACCGCTTTTGCCCTGTTCAACTTGGTTTATTGGGTT GGCTATCTTTACTTATAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmission
name:Gamma-aminobutyric acid receptor subunit gamma-2
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
gene-name:GABRG2
locus:5q31.1-q33.1
cellular-location:Cell junction
transmembrane-regions:274-296 300-322 334-356 444-466
signal-regions:1-39
theoretical-pi:8.6
molecular-weight:54161.78
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4087GenBank Gene DatabaseX15376GenBank Protein Database31637UniProtKBP18507UniProt AccessionGBRG2_HUMAN
synonyms:GABA(A) receptor subunit gamma-2
amino-acid-sequence:>lcl|BSEQ0006917|Gamma-aminobutyric acid receptor subunit gamma-2 MSSPNIWSTGSSVYSTPVFSQKMTVWILLLLSLYPGFTSQKSDDDYEDYASNKTWVLTPK VPEGDVTVILNNLLEGYDNKLRPDIGVKPTLIHTDMYVNSIGPVNAINMEYTIDIFFAQT WYDRRLKFNSTIKVLRLNSNMVGKIWIPDTFFRNSKKADAHWITTPNRMLRIWNDGRVLY TLRLTIDAECQLQLHNFPMDEHSCPLEFSSYGYPREEIVYQWKRSSVEVGDTRSWRLYQF SFVGLRNTTEVVKTTSGDYVVMSVYFDLSRRMGYFTIQTYIPCTLIVVLSWVSFWINKDA VPARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFSALVEYGTLHYFV SNRKPSKDKDKKKKNPAPTIDIRPRSATIQMNNATHLQERDEEYGYECLDGKDCASFFCC FEDCRTGAWRHGRIHIRIAKMDSYARIFFPTAFCLFNLVYWVSYLYL
gene-sequence:>lcl|BSEQ0019445|Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2) ATGAGTTCGCCAAATATATGGAGCACAGGAAGCTCAGTCTACTCGACTCCTGTATTTTCA CAGAAAATGACGGTGTGGATTCTGCTCCTGCTGTCGCTCTACCCTGGCTTCACTAGCCAG AAATCTGATGATGACTATGAAGATTATGCTTCTAACAAAACATGGGTCTTGACTCCAAAA GTTCCTGAGGGTGATGTCACTGTCATCTTAAACAACCTGCTGGAAGGATATGACAATAAA CTTCGGCCTGATATAGGAGTGAAGCCAACGTTAATTCACACAGACATGTATGTGAATAGC ATTGGTCCAGTGAACGCTATCAATATGGAATACACTATTGATATATTTTTTGCGCAAACG TGGTATGACAGACGTTTGAAATTTAACAGCACCATTAAAGTCCTCCGATTGAACAGCAAC ATGGTGGGGAAAATCTGGATTCCAGACACTTTCTTCAGAAATTCCAAAAAAGCTGATGCA CACTGGATCACCACCCCCAACAGGATGCTGAGAATTTGGAATGATGGTCGAGTGCTCTAC ACCCTAAGGTTGACAATTGATGCTGAGTGCCAATTACAATTGCACAACTTTCCAATGGAT GAACACTCCTGCCCCTTGGAGTTCTCCAGTTATGGCTATCCACGTGAAGAAATTGTTTAT CAATGGAAGCGAAGTTCTGTTGAAGTGGGCGACACAAGATCCTGGAGGCTTTATCAATTC TCATTTGTTGGTCTAAGAAATACCACCGAAGTAGTGAAGACAACTTCCGGAGATTATGTG GTCATGTCTGTCTACTTTGATCTGAGCAGAAGAATGGGATACTTTACCATCCAGACCTAT ATCCCCTGCACACTCATTGTCGTCCTATCCTGGGTGTCTTTCTGGATCAATAAGGATGCT GTTCCAGCCAGAACATCTTTAGGTATCACCACTGTCCTGACAATGACCACCCTCAGCACC ATTGCCCGGAAATCGCTCCCCAAGGTCTCCTATGTCACAGCGATGGATCTCTTTGTATCT GTTTGTTTCATCTTTGTCTTCTCTGCTCTGGTGGAGTATGGCACCTTGCATTATTTTGTC AGCAACCGGAAACCAAGCAAGGACAAAGATAAAAAGAAGAAAAACCCTGCCCCTACCATT GATATCCGCCCAAGATCAGCAACCATTCAAATGAATAATGCTACACACCTTCAAGAGAGA GATGAAGAGTACGGCTATGAGTGTCTGGACGGCAAGGACTGTGCCAGTTTTTTCTGCTGT TTTGAAGATTGTCGAACAGGAGCTTGGAGACATGGGAGGATACATATCCGCATTGCCAAA ATGGACTCCTATGCTCGGATCTTCTTCCCCACTGCCTTCTGCCTGTTTAATCTGGTCTAT TGGGTCTCCTACCTCTACCTGTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentaxoncomponentcell junctioncomponentchloride channel complexcomponentdendrite membranecomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocessadult behaviorprocesscellular response to histamineprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocesspost-embryonic developmentprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesssynaptic transmission, GABAergicprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit gamma-3
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRG3
locus:15q12
cellular-location:Cell junction
transmembrane-regions:255-277 281-303 315-337 444-467
signal-regions:1-17
theoretical-pi:7.58
molecular-weight:54288.16
chromosome-location:15
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4088GenBank Gene DatabaseS82769GenBank Protein Database1754749UniProtKBQ99928UniProt AccessionGBRG3_HUMAN
synonyms:GABA(A) receptor subunit gamma-3
amino-acid-sequence:>lcl|BSEQ0006921|Gamma-aminobutyric acid receptor subunit gamma-3 MAPKLLLLLCLFSGLHARSRKVEEDEYEDSSSNQKWVLAPKSQDTDVTLILNKLLREYDK KLRPDIGIKPTVIDVDIYVNSIGPVSSINMEYQIDIFFAQTWTDSRLRFNSTMKILTLNS NMVGLIWIPDTIFRNSKTAEAHWITTPNQLLRIWNDGKILYTLRLTINAECQLQLHNFPM DEHSCPLIFSSYGYPKEEMIYRWRKNSVEAADQKSWRLYQFDFMGLRNTTEIVTTSAGDY VVMTIYFELSRRMGYFTIQTYIPCILTVVLSWVSFWIKKDATPARTALGITTVLTMTTLS TIARKSLPRVSYVTAMDLFVTVCFLFVFAALMEYATLNYYSSCRKPTTTKKTTSLLHPDS SRWIPERISLQAPSNYSLLDMRPPPTAMITLNNSVYWQEFEDTCVYECLDGKDCQSFFCC YEECKSGSWRKGRIHIDILELDSYSRVFFPTSFLLFNLVYWVGYLYL
gene-sequence:>lcl|BSEQ0012498|Gamma-aminobutyric acid receptor subunit gamma-3 (GABRG3) ATGGCCCCGAAGCTGCTGCTCCTCCTCTGCCTGTTCTCGGGCTTGCACGCGCGGTCCAGA AAGGTGGAAGAGGATGAATATGAAGATTCATCATCAAACCAAAAGTGGGTCTTGGCTCCA AAATCCCAAGACACCGACGTGACTCTTATTCTCAACAAGTTGCTAAGAGAATATGATAAA AAGCTGAGGCCAGATATTGGAATAAAACCGACCGTAATTGACGTTGACATTTATGTTAAC AGCATTGGTCCTGTGTCATCAATAAACATGGAATACCAAATTGACATATTTTTTGCTCAG ACCTGGACAGATAGTCGCCTTCGATTCAACAGCACAATGAAAATTCTTACTCTGAACAGC AACATGGTGGGGTTAATCTGGATCCCAGACACCATCTTCCGCAATTCTAAAACCGCAGAG GCTCACTGGATCACCACACCCAATCAGCTCCTCCGGATTTGGAATGACGGGAAAATCCTT TACACTTTGAGGCTCACCATCAATGCTGAGTGCCAGCTGCAGCTGCACAACTTCCCCATG GACGAACACTCCTGCCCGCTGATTTTCTCCAGCTATGGCTATCCCAAAGAAGAAATGATT TATAGATGGAGAAAAAATTCAGTGGAGGCAGCTGACCAGAAATCATGGCGGCTTTATCAG TTTGACTTCATGGGCCTCAGAAACACCACAGAAATCGTGACAACGTCTGCAGGTAGGAAT TTACTGAAAGAGGCACAGCTCTCAAAAGCCAGAGAGGCCTAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesstransmembrane transport
name:Gamma-aminobutyric acid receptor subunit pi
general-function:Gaba-a receptor activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone.
gene-name:GABRP
locus:5q33-q34
cellular-location:Cell junction
transmembrane-regions:243-266 270-292 305-327 417-438
signal-regions:1-16
theoretical-pi:6.99
molecular-weight:50639.735
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4089GenBank Gene DatabaseU95367GenBank Protein Database2197001UniProtKBO00591UniProt AccessionGBRP_HUMAN
synonyms:GABA(A) receptor subunit pi
amino-acid-sequence:>lcl|BSEQ0017152|Gamma-aminobutyric acid receptor subunit pi MNYSLHLAFVCLSLFTERMCIQGSQFNVEVGRSDKLSLPGFENLTAGYNKFLRPNFGGEP VQIALTLDIASISSISESNMDYTATIYLRQRWMDQRLVFEGNKSFTLDARLVEFLWVPDT YIVESKKSFLHEVTVGNRLIRLFSNGTVLYALRITTTVACNMDLSKYPMDTQTCKLQLES WGYDGNDVEFTWLRGNDSVRGLEHLRLAQYTIERYFTLVTRSQQETGNYTRLVLQFELRR NVLYFILETYVPSTFLVVLSWVSFWISLDSVPARTCIGVTTVLSMTTLMIGSRTSLPNTN CFIKAIDVYLGICFSFVFGALLEYAVAHYSSLQQMAAKDRGTTKEVEEVSITNIINSSIS SFKRKISFASIEISSDNVDYSDLTMKTSDKFKFVFREKMGRIVDYFTIQNPSNVDHYSKL LFPLIFMLANVFYWAYYMYF
gene-sequence:>lcl|BSEQ0017153|Gamma-aminobutyric acid receptor subunit pi (GABRP) ATGAACTACAGCCTCCACTTGGCCTTCGTGTGTCTGAGTCTCTTCACTGAGAGGATGTGC ATCCAGGGGAGTCAGTTCAACGTCGAGGTCGGCAGAAGTGACAAGCTTTCCCTGCCTGGC TTTGAGAACCTCACAGCAGGATATAACAAATTTCTCAGGCCCAATTTTGGTGGAGAACCC GTACAGATAGCGCTGACTCTGGACATTGCAAGTATCTCTAGCATTTCAGAGAGTAACATG GACTACACAGCCACCATATACCTCCGACAGCGCTGGATGGACCAGCGGCTGGTGTTTGAA GGCAACAAGAGCTTCACTCTGGATGCCCGCCTCGTGGAGTTCCTCTGGGTGCCAGATACT TACATTGTGGAGTCCAAGAAGTCCTTCCTCCATGAAGTCACTGTGGGAAACAGGCTCATC CGCCTCTTCTCCAATGGCACGGTCCTGTATGCCCTCAGAATCACGACAACTGTTGCATGT AACATGGATCTGTCTAAATACCCCATGGACACACAGACATGCAAGTTGCAGCTGGAAAGC TGGGGCTATGATGGAAATGATGTGGAGTTCACCTGGCTGAGAGGGAACGACTCTGTGCGT GGACTGGAACACCTGCGGCTTGCTCAGTACACCATAGAGCGGTATTTCACCTTAGTCACC AGATCGCAGCAGGAGACAGGAAATTACACTAGATTGGTCTTACAGTTTGAGCTTCGGAGG AATGTTCTGTATTTCATTTTGGAAACCTACGTTCCTTCCACTTTCCTGGTGGTGTTGTCC TGGGTTTCATTTTGGATCTCTCTCGATTCAGTCCCTGCAAGAACCTGCATTGGGGACAAC AAAGGAAGTAGAAGAAGTCAGTATTACTAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionextracellular ligand-gated ion channel activityfunctionGABA-A receptor activityprocesschloride transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocesssignal transductionprocesssynaptic transmission
name:Gamma-aminobutyric acid receptor subunit theta
general-function:Transmembrane signaling receptor activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRQ
locus:
cellular-location:Cell junction
transmembrane-regions:269-289 327-347 612-632
signal-regions:1-21
theoretical-pi:5.76
molecular-weight:72020.875
chromosome-location:X
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:14454GenBank Gene DatabaseAF189259GenBank Protein Database7861736UniProtKBQ9UN88UniProt AccessionGBRT_HUMAN
synonyms:GABA(A) receptor subunit theta
amino-acid-sequence:>lcl|BSEQ0012499|Gamma-aminobutyric acid receptor subunit theta MGIRGMLRAAVILLLIRTWLAEGNYPSPIPKFHFEFSSAVPEVVLNLFNCKNCANEAVVQ KILDRVLSRYDVRLRPNFGGAPVPVRISIYVTSIEQISEMNMDYTITMFFHQTWKDSRLA YYETTLNLTLDYRMHEKLWVPDCYFLNSKDAFVHDVTVENRVFQLHPDGTVRYGIRLTTT AACSLDLHKFPMDKQACNLVVESYGYTVEDIILFWDDNGNAIHMTEELHIPQFTFLGRTI TSKEVYFYTGSYIRLILKFQVQREVNSYLVQVYWPTVLTTITSWISFWMNYDSSAARVTI GLTSMLILTTIDSHLRDKLPNISCIKAIDIYILVCLFFVFLSLLEYVYINYLFYSRGPRR QPRRHRRPRRVIARYRYQQVVVGNVQDGLINVEDGVSSLPITPAQAPLASPESLGSLTST SEQAQLATSESLSPLTSLSGQAPLATGESLSDLPSTSEQARHSYGVRFNGFQADDSIFPT EIRNRVEAHGHGVTHDHEDSNESLSSDERHGHGPSGKPMLHHGEKGVQEAGWDLDDNNDK SDCLAIKEQFKCDTNSTWGLNDDELMAHGQEKDSSSESEDSCPPSPGCSFTEGFSFDLFN PDYVPKVDKWSRFLFPLAFGLFNIVYWVYHMY
gene-sequence:>lcl|BSEQ0012500|Gamma-aminobutyric acid receptor subunit theta (GABRQ) ATGGGCATCCGAGGCATGCTGCGAGCCGCAGTGATCCTGCTGCTCATCAGGACCTGGCTC GCGGAGGGCAACTACCCCAGTCCCATCCCGAAATTCCACTTCGAGTTCTCCTCTGCTGTG CCCGAAGTCGTCCTGAACCTCTTCAACTGCAAAAATTGTGCAAATGAAGCTGTGGTTCAA AAGATTTTGGACAGGGTGCTGTCAAGATACGATGTCCGCCTGAGACCGAATTTTGGAGGT GCCCCTGTGCCTGTGAGAATATCTATTTATGTCACGAGCATTGAACAGATCTCAGAAATG AATATGGACTACACGATCACGATGTTTTTTCATCAGACTTGGAAAGATTCACGCTTAGCA TACTATGAGACCACCCTGAACTTGACCCTGGACTATCGGATGCATGAGAAGTTGTGGGTC CCTGACTGCTACTTTCTGAACAGCAAGGATGCTTTCGTGCATGATGTGACTGTGGAGAAT CGCGTGTTTCAGCTTCACCCAGATGGAACGGTGCGGTACGGCATCCGACTCACCACTACA GCAGCTTGTTCCCTGGATCTGCATAAATTCCCTATGGACAAGCAGGCCTGCAACCTGGTG GTAGAGAGCTATGGTTACACGGTTGAAGACATCATATTATTCTGGGATGACAATGGGAAC GCCATCCACATGACTGAGGAGCTGCATATCCCTCAGTTCACTTTCCTGGGAAGGACGATT ACTAGCAAGGAGGTGTATTTCTACACAGGTTCCTACATACGCCTGATACTGAAGTTCCAG GTTCAGAGGGAAGTTAACAGCTACCTTGTGCAAGTCTACTGGCCTACTGTCCTCACCACT ATTACCTCTTGGATATCGTTTTGGATGAACTATGATTCCTCTGCAGCCAGGGTGACAATT GGCTTAACTTCAATGCTCATCCTGACCACCATCGACTCACATCTGCGGGATAAGCTCCCC AACATTTCCTGTATCAAGGCCATTGATATCTATATCCTCGTGTGCTTGTTCTTTGTGTTC CTGTCCTTGCTGGAGTATGTCTACATCAACTATCTTTTCTACAGTCGAGGACCTCGGCGC CAGCCTAGGCGACACAGGAGACCCCGAAGAGTCATTGCCCGCTACCGCTACCAGCAAGTG GTGGTAGGAAACGTGCAGGATGGCCTGATTAACGTGGAAGACGGAGTCAGCTCTCTCCCC ATCACCCCAGCGCAGGCCCCCCTGGCAAGCCCGGAAAGCCTCGGTTCTTTGACGTCCACC TCCGAGCAGGCCCAGCTGGCCACCTCGGAAAGCCTCAGCCCACTCACTTCTCTCTCAGGC CAGGCCCCCCTGGCCACTGGAGAAAGCCTGAGCGATCTCCCCTCCACCTCAGAGCAGGCC CGGCACAGCTATGGTGTTCGCTTTAATGGTTTCCAGGCTGATGACAGTATTATTCCTACC GAAATCCGCAACCGTGTCGAAGCCCATGGCCATGGTGTTACCCATGACCATGAAGATTCC AATGAGAGCTTGAGCTCGGATGAGCGCCATGGCCATGGCCCCAGTGGGAAGCCCATGCTT CACCATGGCGAGAAGGGTGTGCAAGAAGCAGGCTGGGACCTTGATGACAACAATGACAAG AGCGACTGCCTTGCCATTAAGGAGCAATTCAAGTGTGATACTAACAGTACCTGGGGCCTT AATGATGATGAGCTCATGGCCCATGGCCAAGAGAAGGACAGTAGCTCAGAGTCTGAGGAT AGTTGCCCCCCAAGCCCTGGGTGCTCCTTCACTGAAGGGTTCTCCTTCGATCTCTTTAAT CCTGACTACGTCCCAAAGGTCGACAAGTGGTCCCGGTTCCTCTTCCCTCTGGCCTTTGGG TTGTTCAACATTGTTTACTGGGTATACCATATGTATTAG
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentreceptor complexcomponentsynapsefunctionchloride channel activityfunctionextracellular ligand-gated ion channel activityfunctionGABA-A receptor activityfunctionneurotransmitter transporter activityfunctiontransmembrane signaling receptor activityprocesschloride transmembrane transportprocession transmembrane transportprocessneurological system processprocessneurotransmitter transportprocessregulation of membrane potentialprocesssignal transductionprocesssynaptic transmissionprocesstransmembrane transport

酶

载体

运输工具

药物反应

效应

不良反应